president's report 2008
Post on 22-Mar-2016
223 Views
Preview:
DESCRIPTION
TRANSCRIPT
Education with a global perspective
AL
BA
NY
CO
LL
EG
E O
F P
HA
RM
AC
Y A
ND
HE
ALT
H S
CIE
NC
ES
PR
ES
IDE
NT
’S R
EP
OR
T 2
00
8
CoverF 4/15/09 1:43 PM Page 2
M A N AG I N G E D I T O R
Christine Shields
E D I T O R
Gil Chorbajian
C O N T R I B U T I N G W R I T E R S
Gil ChorbajianJames J. GozzoMark McCartyChristine ShieldsWinifred Yu
C O N T R I B U T I N G P H O T O G R A P H E R S
Gil ChorbajianDon ElliottPatrick RathbunKris QuaChristine Shields
D E S I G N
Coppola Design
CoverF 4/15/09 1:43 PM Page 3
ACPHS 2008 // 1
To be truly educated,students should havea global perspective.
PRES IDENT ’S MESSAGE 2 // FACULTY H IGHL IGHTS 4 // STUDENT H IGHL IGHTS 20 // F INANCIALS 26 // SCHOLARLY ACT IV ITY 28
PrezRepVF 4/15/09 1:35 PM Page 1
In last year’s report, I wrote, “We enjoy a strong reputation as a pharmacy
college, but we aspire to something even greater — to be viewed as a truly
extraordinary institute of higher learning.”
As you will read in the following pages, the College made measurable
strides towards that goal in 2008. The research taking place across all
departments at ACPHS is advancing health care by helping address
several of the world’s most pressing health threats.
PrezRepVF 4/15/09 1:35 PM Page 2
ACPHS 2008 // 3
Susan Ludeman, Ph.D., for example, has an
active grant from the National Cancer Institute
which is examining how genetic factors influ-
ence the efficacy of chemotherapeutic drugs.
Thomas Lodise, Pharm.D., has received four
separate grants to determine the best courses
of treatment for patients infected with MRSA, a
potentially deadly bacteria that has been
described by NIH as ’a serious public health
concern.’
The College’s Pharmaceutical Research
Institute, headed by Shaker Mousa, Ph.D.,
marked its fifth anniversary in 2008 by securing
the largest single grant in its history. PRI will
receive $1.37 million over five years to help
develop an antidote for anthrax as part of a
joint effort with three other institutions.
Carlos Feleder, M.D., Ph.D., received an NIH-
funded grant in 2008 to study the role of the
spleen in managing fever. On the other end of
the temperature spectrum, Alex Steiner,
Pharm.D., Ph.D., is working to understand how
hypothermia may play a key part in preserving
tissue in patients with severe sepsis.
Given the quality of the research taking place
at ACPHS and the global importance of those
subjects being studied, it is little surprise that
investigators from around the world are seeking
to collaborate with our institution. The College
is working with academic, pharmaceutical and
biotechnology institutes in nearly 20 countries,
including: Australia, China, Japan, Egypt, Saudi
Arabia, Turkey, Switzerland, Germany,
Argentina, Brazil and Australia.
One of the primary beneficiaries of the research
taking place here is our students. Regardless of
their academic focus, students at ACPHS are
encouraged to participate in research projects.
The opportunity to work closely with faculty
and contribute in a meaningful way to their
research is one not often afforded to undergrad-
uates, and more students at the College are tak-
ing advantage of these unique opportunities.
Jaclyn Hosmer is one such student. She is a
third year Pharm.D. student who is working
with Assistant Professor Luciana Lopes,
Pharm.D., Ph.D., in researching new treat-
ments for skin cancer. There is also Alex
Villanueva, a fourth year student in the B.S.
in pharmaceutical sciences program, who
received a prestigious “Gateway to Research”
scholarship from the American Foundation
for Pharmacy Education to study hypoten-
sion with his mentor, Dr. Feleder. Several
more examples of exemplary student
research can be found in this Report.
When one considers the impact of these and
other initiatives, it becomes clear how our
research programs are distinguishing the
College in the region, across the nation and
around the world. As importantly, these pro-
grams are providing our students with a
wider range of educational opportunities —
from laboratory research to patient care. The
result is graduates who have a better under-
standing of the full spectrum of health care
and a global perspective on how best to
apply their knowledge.
PRESIDENT ’S MESSAGE
James J. Gozzo, Ph.D.
PrezRepVF 4/15/09 1:35 PM Page 3
Department of Pharmaceutical Sciences assis-
tant professors Carlos Feleder, M.D., Ph.D, and
Alex Steiner, Pharm.D., Ph.D. are looking at tem-
perature in a new light in two separate research
projects at ACPHS. Both are taking an alternative
look at the role of temperature in fighting infec-
tion. Dr. Feleder recently won a grant to study
the role of the spleen in fever, while Dr. Steiner is
studying hypothermia’s effect on sepsis.
Though many studies have been conducted on
the liver’s impact on fever, the spleen’s role
remains relatively unknown. Dr. Feleder hopes
to change that with a $231,000 research grant
from the National Institutes of Health (NIH).
According to his research, the spleen plays an
important role in managing fever by releasing a
chemical that caps fever, preventing body tem-
perature from reaching dangerous levels. The
goal of his grant is to identify the chemical or
’factor’ being produced by the spleen during
fever and study its mechanism of action.
“Most research in this area has focused on the
liver as the key to managing fever,” says Dr.
Feleder. “Our initial findings show that the
activity of cells in the liver during fever is, in
fact, influenced by chemicals produced in the
spleen. If we understand how the body sets
upper limits on temperature and learn to influ-
ence this process, we can allow the body to
enjoy the benefits of fever and minimize the
potential threats, thereby accelerating the
recovery process.”
In the 1970s and 1980s, a University of Michigan
Medical School researcher named Matthew
Kluger challenged long held beliefs about fever.
Medicine’s approach to fever was to lower
body temperature in the majority of cases.
However, by infecting desert lizards with bac-
terium, he proved fever could be beneficial. In a
terrarium with hot and cold temperatures, he
gave the animals the option of voluntarily rais-
ing their body temperatures and found that
those who chose to raise their temperatures
survived. Fever plays a critical role in fighting
infection because immune cells are more effec-
tive in killing invading bacteria at higher tem-
peratures.
Similar to Kluger’s view of fever, Dr. Steiner sees
potential in the power of hypothermia. During
severe infection (systemic inflammation or sep-
sis), 90 percent of patients develop fever, and
10 percent develop hypothermia. Clinicians
think of hypothermia as a “wrong” reaction and,
much of the time, their approach is to raise
body temperature. With severe sepsis the lead-
ing cause of death among patients in non-coro-
nary intensive care units, hypothermia might
actually save tissues by lowering metabolic
demands and increasing profusion, Dr. Steiner
says. Fever, during severe infection, can dam-
age tissues, and hypothermia could possibly be
the body’s “strategy of last resort.”
“Body temperature influences everything, every
chemical reaction in your body,” Dr. Steiner
explains. “We’re not talking about cooling
patients; we’re talking about not heating septic
patients who spontaneously become hypother-
mic. Inaction might be best.”
While doing postdoctoral research in Arizona,
Dr. Steiner noted that rats with severe sepsis
choose to stay in a cool environment where
they can develop hypothermia, an indication
that hypothermia might be a natural physiolog-
ical response. Recognizing a gap in hypother-
mia research, he decided to pursue it. His
research at ACPHS thus far indicates that sep-
tic rats allowed to develop hypothermia (by
being kept in a cool environment) suffer less
tissue injury than rats forced to develop fever
(by being kept in a warm environment). He is
now carrying out experiments to identify which
temperature-dependent processes are primarily
responsible for such protection. During fever
and hypothermia, Dr. Steiner measures tissue
energy in the liver and kidney for signs of injury.
Both Dr. Feleder and Dr. Steiner see room for
collaboration in the future, and they say often
talk to each other about their research. They
can hardly avoid this, as their offices are next to
each other in the Biosciences Research Building
at ACPHS. Aside from temperature, they have
something else in common—another of Dr.
Feleder’s research projects focuses on the
brain’s response to sepsis.
Body temperature influences every chemical reaction in our bodies. In separateresearch projects, Dr. Carlos Feleder and Dr. Alex Steiner are taking an alternativelook at the role of temperature in fighting infection.
Dr. Alex Steiner, with research assistant Cathy Krall,
measures tissue energy in the liver and kidney during
fever and hypothermia.
Running hot and cold Investigating temperature’s role in fighting infection
PrezRepVF 4/15/09 1:35 PM Page 4
ACPHS 2008 // 5
Dr. Carlos Feleder is investigating the role of the spleen in managing fever.
PrezRepVF 4/15/09 1:35 PM Page 5
A large part of Dr. Ludeman’s current research
relates to cancer. Before landing at ACPHS, she
held positions as an associate professor in the
Division of Medical Oncology, Department of
Medicine, at Duke University Medical Center
and assistant professor in the Division of
Experimental Therapeutics and Pharmacology,
Department of Oncology, at the Johns Hopkins
University Medical Institutions. Her opportuni-
ties through these institutions have led to some
exciting research collaborations; she currently
has two active grants totaling $434,296.
One, through the National Cancer Institute,
involves the chemistry and pharmacology of
cyclophosphamide and related alkylating
agents, anticancer drugs which act by modify-
ing DNA. Many chemotherapeutics target DNA
in cancer cells so as to disrupt cell function and
cause cell death, explains Dr. Ludeman. But the
body’s natural defense mechanisms include
repair “machinery” that will attempt to fix the
damage to DNA.
“If we can pinpoint this repair sequence, we
may be able to stop it,” Dr. Ludeman says, thus
increasing the efficacy of chemotherapy.
The study also includes a pharmacogenetic
component. Cyclophosphamide and related
alkylating agents must be activated in the liver
to be effective, but, depending on hepatic
enzyme activity, these drugs are subject to
competing reactions. The alternative pathways
lead to toxic side effects that can significantly
decrease the drugs’ effectiveness.
“A genetic factor may predetermine if the
drugs will work,” says Dr. Ludeman. “With most
chemotherapy, weeks or months are required
before you see the effects.” By knowing ahead
of time if a drug has a chance of being effec-
tive, oncologists might be able to avoid wasting
precious treatment time as well as undesirable
side effects.
Another grant, from the National Institute on
Aging, in collaboration with North Carolina
State University, involves antioxidant metabo-
lism in the brain. Research suggests that the
loss of antioxidants, especially glutathione, may
speed the aging process and the onset of dis-
eases such as Parkinson’s and Alzheimer’s.
Although scientists have tried to increase levels
of glutathione to slow the effects of aging, oral
doses have been ineffective.
Glutathione is naturally synthesized in the brain
from three amino acids. Dr. Ludeman’s role is to
synthesize molecules related to these “building
blocks,” or prodrugs, which are more readily
transported across the blood brain barrier. The
prodrugs contain a “label” which can be visual-
ized through MRI techniques. Working with
rats, the team uses brain imaging to non-inva-
sively follow the uptake and conversion of
these prodrugs to glutathione.
Over the years, Dr. Ludeman has worked close-
ly with researchers with many different areas of
expertise and from all over the world to come
up with some innovative treatments, several of
which she holds patents on.
One project at Johns Hopkins resulted in
Gliadel™, a clinically used drug delivery system
for brain cancer. Gliadel is a dime-sized wafer
composed of a polymer which slowly releases
an anticancer agent. Multiple wafers are
implanted in the cavity left after a surgeon
removes as much of a brain tumor as possible;
the purpose of the implant is to release drug
directly at the site of any remaining cancer
cells. The project was a multi-disciplinary effort
involving neurosurgeons, oncologists, chemical
engineers, polymer chemists, organic chemists,
pharmacologists, biologists and representatives
from the pharmaceutical industry.
“Working in a medical center you get to see the
impact of your projects and how important col-
laborations between different disciplines are,”
says Dr. Ludeman.
Another patent derived from chemistry, cell
biology and pharmacology is for a dye that
detects certain types of stem cells by causing
them to light up under spectroscopy. Once iso-
lated from, for example, marrow or cord blood,
these stem cells can be injected into the patient
in the hopes of a therapeutic response such as
tissue regeneration or a treatment for leukemia.
The dye is commercially available for research
purposes and cells isolated using this dye are
being tested as part of regenerative tissue ther-
apies in clinical trials at medical centers around
the United States.
Susan Ludeman, an associate professor of organic chemistry in the Department of Arts and Sciences, is working across disciplines to delve into the mechanisms of diseases such as cancer andAlzheimer’s and develop novel approaches to their treatment.
The Right ChemistryCutting Edge Research Crosses Disciplines
PrezRepVF 4/15/09 1:35 PM Page 6
ACPHS 2008 // 7
“It is performing well in a major clinical trial with
people who are in danger of losing their limbs,”
explains Dr. Ludeman.
After spending the fall semester setting up her
new lab, Dr. Ludeman is ready to get students
involved in her research and has three, includ-
ing one freshman, signed on for the spring.
“The interdisciplinary nature of Dr. Ludeman’s
work provides students an excellent opportuni-
ty to participate in cutting-edge research that
spans the fields of chemistry, biochemistry and
pharmacology,” says David Clarke, Ph.D., Arts
and Sciences department chair.
“My own undergraduate research experience
ignited my excitement for chemistry and
became the springboard for my decision to
enter graduate school and pursue an academic
career,” Dr. Ludeman says. “I am a huge propo-
nent of undergraduates being given the oppor-
tunity to discover their own interests and paths.
It’s exciting to see students make something
that has never been made before.”
Dr. Ludeman holds a patent on an assay for detecting certain types
of stem cells. The assay is known commercially as Aldefluor™ and
its key component is a dye known as BODIPY aminoacetaldehyde.
This dye, which was designed by Dr. Ludeman, is shown as an
energy-minimized, van der Waals surface model (ChemDraw 3D).
Dr. Ludeman demonstrates a rotary evaporator
to Mike D’Alessandro, a second-year student in
the Pharmaceutical Sciences program.
Susan Ludeman’s research involves the chemistry and pharmacology
of cyclophosphamide (known clinically as Cytoxan™) and related
alkyating agents. Shown is an energy-minimized, van der Waals
surface structure of cyclophosphamide (ChemDraw 3D).
PrezRepVF 4/15/09 1:35 PM Page 7
PrezRepVF 4/15/09 1:35 PM Page 8
ACPHS 2008 // 9
With students now in all four years of the pro-
gram and every course in all three tracks
offered for the first time, several new part-time
faculty members were added to the depart-
ment during the year, joining associate profes-
sors Indra Balachandran, Ph.D., and Elyse
Wheeler, Ph.D.; Assistant Professor Victoria
Peters, M.S. Ed.; and Instructor Joe Walker, B.S.
In addition, Lawrence Lansing, M.D., has joined
the department in a full-time capacity. A Board
Certified Pathologist and active researcher, Dr.
Lansing brings a unique clinical insight to the
classroom.
More courses were added as well. The CLS pro-
gram alone implemented 11 new courses and
associated labs in 2008 including classes in
advanced hematology, immunohematology and
molecular techniques.
Both the cytotechnology and the clinical lab-
oratory sciences tracks have graduated their
first bachelor’s degree students while five stu-
dents received post-baccalaureate Certificates
in Cytotechnology. All of the graduates passed
the American Society of Clinical Pathology
Registry exam required to work as cytotech-
nologists and are employed in hospitals and
private labs.
The University of Rochester Medical Center,
New York Presbyterian Hospital and Long Island
Jewish Medical Center were added as new clini-
cal affiliations, providing additional opportunities
for students in the cytotechnology program.
Currently, there are more than 20 clinical affili-
ates in hospitals and private laboratories in the
Capital District and across the country.
The program has grown not only in size, but
also has acquired some crucial new equip-
ment. Since moving to the cytotechnology
classroom at the College’s facility at 84
Holland Ave., the student experience has been
enhanced by the addition of a ThinPrep T2000
processor made possible with a grant from the
Bender Family Foundation and the help of
Hologic. ThinPrep is one of two FDA-approved
methods for making liquid-based preparations
of specimens in a cytology lab. With the new
processor, the program can increase teaching
cases of ThinPrep material and offer hands-on
experience to students.
In addition, the program has received support
from BD Tripath to increase SurePath cases,
another method of making liquid-based gyneco-
logic, non-gynecologic and fine needle aspirations.
A multi-headed review scope received from
Albany Medical Center helps faculty to demon-
strate the criteria for diagnosis of infections,
pre-malignant changes and malignancies simul-
taneously to nine students. It is also used
extensively for reviewing students’ unknown
cases.
“In this format, each student learns from,
not only his or her unknown cases, but also
from those of their classmates,” says Dr.
Balachandran, director of the cytotechnology
program. “This, in turn, increases the students’
confidence in criteria and diagnosis of disease
processes.”
The CLS program has made progress this year
as well, completing its self-study, a major step
toward receiving accreditation by the National
Accrediting Agency for Clinical Laboratory
Science (NAACLS).
The Department of Health Sciences at ACPHS expanded in many exciting directions in 2008. Thedepartment made significant progress toward the complete implementation of the three tracks withinthe B.S. in Biomedical Technology program: Clinical Laboratory Science (CLS), Cytotechnology andPhysician Assistant Studies, further enhancing the range of academic programs now offered at the College.
Putting the Health Sciences into ACPHSGrowing Enrollment, Expanded Programs
PrezRepVF 4/15/09 1:35 PM Page 9
“The Clinical Laboratory Science program has
achieved ’Serious Applicant’ status through the
NAACLS, which allows our students to sit for
certifying and licensing exams,” says program
director Vickie Peters. “Full accreditation is
expected by May of 2009.”
The program is also finalizing affiliation agree-
ments with Hudson Valley and Schenectady
Community Colleges.
ACPHS also offers a unique program with
Albany Medical College’s (AMC) Center for
Physician Assistant Studies. The joint program
begins at ACPHS with academic preparation
and training in basic science and a clinical labo-
ratory specialty. Upon completion, in January of
their senior year, students enter a two-year M.S.
program in Physician Assistant Studies at the
Medical College. The program offers an excel-
lent pathway for students seeking to “lock in”
one of the coveted spots in AMC’s highly com-
petitive physician assistant program.
The department promises to grow even more
during the 2008–2009 academic year. Hassan
El-Fawal, Ph.D., has joined the College as the
new chair of Health Sciences. Dr. El-Fawal
received his B.Sc. in Entomology and Pesticide
Chemistry from the University of Alexandria,
Egypt, M.Sc. in Biomedical Sciences from
University of Guelph, Canada, Ph.D. in
Biomedical and Environmental Sciences
from Virginia Polytechnic Institute and State
University and postdoctoral fellowship at the
USEPA in Research Triangle Park, N.C. A spe-
cialist in the area of toxicology, he previously
worked at Mercy College School of Health
Clinical Laboratory Sciences Director
Vickie Peters spends a great deal
of time in the lab with students.
PrezRepVF 4/15/09 1:35 PM Page 10
ACPHS 2008 // 11
Professions and Natural Sciences and New York
University School of Medicine. His full-time
appointment as professor and chair of Health
Sciences took effect in January. He also holds
a joint appointment in the Department of
Pharmaceutical Sciences.
With more than 20 years of academic and
research experience, Dr. El-Fawal does not hesi-
tate to cross lines between the humanities and
the basic and applied sciences. He has devel-
oped and taught biomedical curricula for such
diverse programs as Physical and Occupational
Therapy, Communication Disorders, Physician
Assistant Studies, Acupuncture and Oriental
Medicine, Nursing and Clinical Laboratory
Sciences. In addition he has mentored students
in Neuroscience, Pharmacology and
Environmental Medicine.
Dr. El-Fawal was attracted to ACPHS because
of its “entrepreneurial spirit and mission to pro-
vide a quality education in an environment hos-
pitable to students and researchers, alike.” He is
particularly impressed by the College’s accom-
plishments and growth, both physically and
intellectually, in the past decade though efforts
such as PRI, graduate degree offerings and the
ability to attract cutting-edge researchers.
“The College is poised to write a new chapter in
biomedical advancement and education.” He
sees himself a part of that vision.
“We are defining Health Sciences in the broad-
est sense, establishing a foundation that is
inclusive of such cutting-edge growth fields
as biotechnology, molecular diagnostics,
immunotechnology and environmental health,
as well as being at forefront of clinical diagnos-
tics,” says Dr. El-Fawal. “The cornerstone of this
foundation is to be student-centered and build
an intellectual partnership between faculty,
students and the institution. ACPHS has the
intellectual capital, the will and the energy to
be a pioneer in biomedical education.”
A ten-headed microscope allows Joe Walker, education coordinator
for cytotechnology, and students to simultaneously review cases.
PrezRepVF 4/15/09 1:37 PM Page 11
Across the globe, pharmaceutical researchers, instructors and students are getting a glimpse of the workbeing done at Albany College of Pharmacy and Health Sciences. At the same time, they’re sharing theirknowledge with ACPHS students, faculty and researchers. The surge in international exchanges aroundthe world bodes well for the future of medicine and the treatment of major illnesses.
Going Global
PrezRepVF 4/15/09 1:37 PM Page 12
ACPHS 2008 // 13
Doing pharmaceutical research with scientists
from other countries has numerous benefits,
says Shaker Mousa, Ph.D., executive vice presi-
dent and chairman of the Pharmaceutical
Research Institute at ACPHS. Under Dr. Mousa’s
direction, the Institute has obtained dozens of
research grants and equipment donations total-
ing more than $13 million since its establish-
ment in 2002. Now located in a spacious facili-
ty in Rensselaer, N.Y., PRI has grown from three
employees to 48 over the past five years, with
international experts in fields such as nanotech-
nology, medicinal chemistry, molecular biology,
cell biology and drug delivery and development
on staff.
“Our research collaborations bring international
recognition to the College and will draw gradu-
ate students to ACPHS from all over the world,”
says Dr. Mousa, a native of Egypt and the
founding director of PRI. “They make people
aware of our educational and research capabili-
ties while attracting scientists who bring new
dimensions to our work.”
Collaborations help pharmaceutical researchers
fulfill their ultimate goal: the advancement of
science. “The goal at the end of the day is to
save human lives,” Dr. Mousa says. “Science has
no boundaries, particularly when it comes to
benefiting mankind . Diversity and partnerships
are our greatest chance for success.”
Over the past five years, Dr. Mousa has devel-
oped national and international collaborations
with academic, pharmaceutical and biotechnol-
ogy institutes in the U.S., Japan, South Korea,
Saudi Arabia, Kuwait, the United Arab Emirates,
Egypt, Germany, France, England, Turkey,
Denmark, Australia, India and others.
THE MIDDLE EASTOne of the many collaborations now underway
involves work with researchers in the Middle
East on new approaches for treating breast
cancer. Breast cancer kills millions of women
around the world each year and affects millions
more. In the course of treatment, some women
become resistant to chemotherapy. Others
become very ill from the systemic effects of
anti-cancer drugs.
“We are trying to overcome the resistance
problem, so that the chemo can still be effec-
tive,” Dr. Mousa explains. “We’re also using nan-
otechnology to deliver chemo directly to the
cancer cells, so we can eliminate the horrible
side effects that result from the destruction of
healthy cells.”
Dr. Murat Yalcin from Uludag University in Turkey, shown here with ACPHS students
Evan Kujawski and Rebecca Reynolds, has assisted PRI with breast cancer research.
PrezRepVF 4/15/09 1:37 PM Page 13
That’s where Olfat Shaker, M.D., came in. Dr.
Shaker, a professor of medical biochemistry
and molecular biology at Cairo University in
Egypt, was a visiting scholar at PRI in 2008.
Researchers at PRI provided technical support
and advice on nanoparticle formulations, while
Dr. Shaker offered data on tumor growth,
tumor angiogenesis and the impact of anti-
tumor agents on body organs. Their collabora-
tion will produce agents that will be tested on
animals, with the hopes of advancing to human
trials one day. The technology will also be
applied to liver cancer.
“We are starting to publish our joint works,” Dr.
Mousa says. “The next step is for us to go to
Egypt, where the incidence of liver cancer is
very high, to examine novel targets in liver can-
cer models and learn about the research taking
place there.”
Dr. Mousa also has the help of another overseas
researcher in a separate breast cancer project,
funded by a $406,400 grant from the United
States Department of Defense. Murat Yalcin,
Ph.D., a veterinarian researcher from Uludag
University in Bursa, Turkey, is here to assist
with research into non-anticoagulant heparin
(NACH) compounds and the delivery of
chemotherapy into breast cancer cells with
minimal impact on normal cells. During treat-
ment, these compounds may reduce the risk of
blood clotting, which is one of the most signifi-
cant and deadly side effects of chemotherapy.
PRI is also exploring the use of low molecular
weight heparin (LMWH) derivatives in the
treatment of renal cancer with researchers at
several universities in Dubai and Kuwait, where
the disease is more common than here in the
U.S. “There is direct evidence that these drugs
have an anti-cancer effect and that the anti-
Dr. Olfat Shaker, left, a professor of medical biochemistry and molecular biology from Cairo University in Egypt, shown
here with ACPHS student Anhtung Duong, visited PRI to share expertise in the areas of tumor growth and angiogenesis.
Panorama of a slide
showing breast adenocarcinoma,
viewed under a microscope.
A jumbled mass of cancer
forces its way in healthy
liver tissue in this
microscopic view.
PrezRepVF 4/15/09 1:37 PM Page 14
ACPHS 2008 // 15
clotting effect is a secondary benefit,” Dr.
Mousa says.
The Institute’s work with LMWH derivatives
includes treating pain in patients with sickle cell
disease, an inherited blood disorder that causes
abnormal hemoglobin and disrupts blood flow.
Sickle cell disease affects as many as 3 in 10
people in Saudi Arabia as well as about 50,000
people in the U.S., most of them African-
American.
Findings from that research—which was
dubbed a “landmark study” by the American
Hematological Society—helped create guide-
lines for managing pain in sickle cell patients.
“We’re now doing a follow-up trial that will
show how to give home treatments for the
painful crisis,” Dr. Mousa says. “Now, instead of
going to the hospital to get an injection, we’re
coming up with a formula that patients can
self-administer at home.”
The sickle cell studies and other studies in the
United Arab Emirates have spawned the prom-
ise of another type of collaboration—providing
ACPHS faculty with the chance to teach contin-
uing education classes and workshops to phar-
macy graduates in Dubai. “It would a great
opportunity for our faculty,” Mousa says. “It
would be major exposure for the College, and
we would be teaching graduates from all over
the world.”
WORKING IN THE WESTThe Middle East is only one region of the world
working with PRI researchers. The institute is
also collaborating with scientists at the
University of Frankfurt in Germany. According
to Dr. Mousa, German scientists are very
advanced in embryonic stem cell research,
which may someday be used to treat vascular
diseases and thrombosis, repair tissue damage
caused by spinal cord injuries and trauma and
possibly even cure diabetes and other autoim-
mune diseases.
Dr. Mousa says he hopes to combine nanotech-
nology with non-embryonic stem cell research
to create a delivery system that will implant the
stem cells with the least amount of side effects.
Stem cells will then help regenerate tissue that
will help repair damaged tissue including
nerves, blood vessels and bones. “We could
potentially repair the heart in people with heart
failure,” he adds.
That same enthusiasm is being directed at
another project that seeks to reverse vision loss
in people with diabetes and macular degenera-
tion. Joining PRI researchers in that endeavor is
Evgeny Dyskin, M.D., who earned his Ph.D. from
the Medical Radiological Research Centre in
Obninsk, one of Russia’s leading scientific cen-
ters. Dr. Dyskin is continuing his ophthalmology
research at PRI and testing novel anti-angio-
genesis targets that prevent and reverse vision
loss in patients with diabetic retinopathy and
macular degeneration.
The project has also received the assistance of
ophthalmology and biotechnology researchers
from Showa University in Tokyo, Japan, who
spent three months at PRI.
Closer to home, PRI is part of a joint project
with the University of Toronto, Rensselaer
Polytechnic Institute and Biophage Pharma Inc.,
a Canadian company, to develop an antidote
for anthrax, a potentially deadly disease caused
by the naturally occurring Bacillus anthracis
bacterium. The group recently received a five-
year $6.2 million grant for the project, of which
PRI will receive $1.37 million.
The PRI research team will focus on optimizing
the concentrations of ’ingredients’ in the anti-
dote and look for ways to extend the product’s
shelf life. Though anthrax sometimes can be
treated with antibiotics, some forms of the dis-
ease are resistant to any form of therapy. An
antidote would provide an additional form of
treatment, one that might be more effective in
the latter stages of the disease when standard
treatments are less effective.
Anthrax bacteria are rod-shaped and highly pathogenic. Two forms
of the disease occur: in the lungs and on the skin. The skin infection
is usually treatable with antibiotics. Inhalation of anthrax spores and
the development of pulmonary anthrax is often fatal unless antibiotics
can be administered before the symptoms appear.
Stem cells can differentiate into any other cell type. There are three
main types of mammalian stem cell: embryonic stem cells, derived
from blastocysts; adult stem cells, which are found in some adult
tissues; and cord blood stem cells, which are found in the umbilical cord.
PrezRepVF 4/15/09 1:37 PM Page 15
WORLD-WISE RESEARCH AND LEARNINGInternational research is happening in the labo-
ratories on campus, as well; a reflection of the
pharmaceutical industry’s efforts to do more
global research and the College’s drive to pro-
vide students a more worldly education.
Carlos Feleder, M.D., Ph.D., an assistant profes-
sor in the Department of Pharmaceutical
Sciences, has been working with Xiujuan Yao, a
Ph.D. candidate from the China Pharmaceutical
University in Nanjing. Yao is at ACPHS for two
years on a fellowship to supervise research
activities related to a grant Dr. Feleder received
from the National Institutes of Health to study
the role of the spleen in managing fever (see
page 8).
In addition, Dr. Feleder is working with Rodolfo
Cutrera, Ph.D., a professor in the Department of
Physiology at the University of Buenos Aires in
Argentina. Their research is looking at how the
central nervous system mediates the initiation
of septic shock and how prenatal immune chal-
lenges, such as stress and infections, affect
behavior during adulthood. Their work has
been published in several journals.
Dr. Feleder is also working with M. Sertac
Yilmaz, M.D., Ph.D., a visiting scientist from
Uludag University School of Medicine in Bursa,
Turkey. Together with William Millington, Ph.D.,
chair of the Department of Pharmaceutical
Sciences, they are studying and publishing arti-
cles on the role of the brain in septic and hem-
orrhagic shock. Along with another scientist
from Uludag University, they are planning a
symposium on the topic at a scientific meeting
in Antalya, Turkey, in November 2009.
Separately, Dr. Millington has been working
with Sinan Cavun M.D., Ph.D., and Gokhan
Goktalay, M.D., Ph.D., associate professors of
pharmacology at Uludag. The trio is studying
a brain chemical called glycyl-glutamine
(Gly-Gln) and its role in the prevention of
addiction to drugs such as nicotine and mor-
phine. Their research on rats has shown that
Gly-Gln reduces the effects of morphine and
nicotine and the severity of withdrawal from
these drugs.
Dr. Cavun has taken the research even further
in Uludag, using microdialysis techniques not
available at ACPHS. “He showed that Gly-Gln
inhibits the euphoria that a morphine high
produces by preventing the morphine-induced
release of dopamine in the brain reward path-
way,” Dr. Millington says. Meanwhile, Dr.
Goktalay is in Ankara, Turkey, testing whether
Gly-Gln is effective in animal models of anxiety
and epilepsy.
Another faculty member working with interna-
tional researchers is Robert M. Levin, Ph.D., pro-
fessor of pharmaceutical sciences. Most of Dr.
Levin’s research is in lower urinary tract func-
tion and dysfunction in both males and
females. He has worked with several scientists
from Maruzen Pharmaceuticals of Hiroshima,
Japan to study the use of kohki tea for the
treatment of urinary bladder dysfunction due
to an enlarged prostate. Kohki is a leaf rich in
antioxidants that comes from a plant in China,
and is formulated into a medicinal tea by
Maruzen.
Dr. Levin also works with other international
researchers from Taiwan, Korea and China on
studies involving lower urinary tract dysfunc-
tions including incontinence and interstitial cys-
titis in women.
Still to come is a new venture between Luciana
Lopes, PhD., an assistant professor of pharma-
ceutical sciences at ACPHS, and Maria Vitoria
Bentley, Ph,D. of the Pharmacy School of
Ribeirao Preto at the University of Sao Paulo
in Brazil. The two researchers will study the
development and characterization of new
transdermal delivery systems. Jaclyn Hosmer,
a Pharm.D. student at ACPHS, is also involved
in the research (see story page 20).
Dr. William Millington is working with scientists
from Turkey on the role of the brain chemical
glycyl-glutamine in preventing drug addiction.
Ophthalmology and biotechnology researchers from Showa University in Tokyo,
shown here with Dr. Shaker Mousa and ACPHS President James J. Gozzo,
spent three months at PRI on cutting-edge research to reverse vision loss in
people with diabetes and macular degeneration.
PrezRepVF 4/15/09 1:38 PM Page 16
ACPHS 2008 // 17
MORE STUDENTS ABROAD At the same time, more and more ACPHS
students are studying at foreign universities.
ACPHS already has programs with the
University of Basel in Switzerland and Maruzen
Pharmaceuticals and is working on developing
more.
In Basel, for example, sixth-year Pharm. D. stu-
dents engage in clinical testing at the University
Hospital and gain experience working in Swiss
hospitals and retail pharmacies. They also
spend time at a heroin clinic, visit corporations
like Roche and Novartis and complete research
projects that, in some cases, result in publica-
tions, says Kevin Hickey, Ph.D., an assistant pro-
fessor in the Department of Arts and Sciences,
who has overseen the program since 2004. In
exchange, Dr. Hickey invites students from
Basel to do research with ACPHS faculty. “The
hope is that this partnership will grow into not
only more student exchanges, but also faculty
collaborations and exchanges and innovative
teaching technologies such as sharing lectures
via video-streaming,” he says.
Over in Hiroshima, Japan, students have the
chance to do research at Maruzen
Pharmaceuticals, a company specializing in
natural products. Since 2001, Dudley Moon,
Ph.D., professor of biological sciences, has
coordinated a five-week internship for ACPHS
students at Maruzen R&D Centers. The experi-
ence, which also meets the requirements for a
Pharm.D. rotation, kicks off with study of the
Japanese language.
Anna Leung, 23, of New York City, had the
opportunity to go to Maruzen in the summer of
2008. While there, she did research on natural
products. “We extracted, purified and tested
chemicals from plants,” she said. “After work
hours, the staff was kind enough to show us
around. There were also many cultural events
organized to help us experience Japan.”
Even with these well-established programs, the
College continues to forge new ties and, in
coming months, will offer students the chance
to study at the University School of Pharmacy
in Yeditepee, Turkey, and Uludag University
School of Medicine in Bursa, Turkey. The college
is also on the brink of establishing exchanges
with the National University of La Plata, School
of Pharmacy, in Argentina; the University of
Belgrano, School of Pharmacy, in Buenos Aires,
Argentina and the University of Santiago de
Compostela, School of Pharmacy, in Spain.
“We are developing joint training programs for
both undergraduate and graduate students,
whereby we will exchange students and facul-
ty,” Dr. Feleder says. “We will also apply for a
grant for the project from the European Union,
which provides support for these kinds of inter-
actions between universities.”
For his part, Andy Zheng, Ph.D., an assistant
professor of pharmaceutical sciences, is trying
to build ties to Fudan University in Shanghai
and hoping to create education and research
opportunities for graduate students and rota-
tions for Pharm.D. students. “We want to try
and send graduate students to China to study
traditional Chinese and herbal medicine,” he
says.
Meanwhile, in the Department of Arts and
Sciences, Assistant Professor Ray
Chandrasekara, Ph.D., is working to establish
research and rotation opportunities for ACPHS
students in Southeast Asia, most notably
Cambodia and Vietnam, especially for students
interested in going on to medical school.
“These experiences are eye opening and would
set them apart from other students,” Dr.
Millington says.
Working with international scientists creates
other possibilities too. Last June, the connec-
tion with Maruzen gave rise to the first-ever
Nature-ceuticals Symposium at ACPHS.
According to Dr. Moon, chair of the event’s
organizing committee, the conference exposed
faculty and students to natural products, which
have long been an important part of Japanese
culture and are becoming increasingly popular
among U.S. consumers. Highlights of the event
included a keynote address by David M.
Eisenberg, director of the Division of Research
and Education in Complementary Medicine at
Harvard Medical School and a Japanese tea
ceremony. Dr. Moon hopes to stage another
conference in 2011.
“To be truly educated, students should have a
global perspective,” says Dr. Millington.
Based on the number of collaborations in place
and under development, an increasing number
of students at ACPHS are now gaining that
global perspective—both scientifically and
culturally. The result is graduates who leave
the campus with a greater sense of themselves
and the world around them.
A Japanese tea ceremony was one of the
highpoints of the Nature-ceuticals Symposium
held at ACPHS in June 2008.
Extracts of tea leaves have been used medicinally in East Asia for
hundreds of years. Dr. Robert Levin has worked with scientists in
Japan to study their use to treat bladder dysfunction.
PrezRepVF 4/15/09 1:38 PM Page 17
Dr. Lodise, an associate professor in the
Department of Pharmacy Practice at ACPHS,
has received four grants totaling $469,598 to
study methicillin-resistant staphylococcus
aureus (MRSA) and the various antibiotics used
to treat infections from this potentially deadly
bacteria.
“The dramatic increase in MRSA infections—
in both health care and community settings—
is a cause for great concern for health care
practitioners,” says Dr. Lodise. “One of the goals
of this research is to determine the best course
of treatment for patients infected with MRSA.”
MRSA is a type of staph infection that is
demonstrating increased resistance to the
medications typically prescribed to treat it.
According to the National Institutes of Health
(NIH), “MRSA has evolved from a controllable
nuisance into a serious public health concern.”
MRSA can present in two forms. The first,
Health Care Associated MRSA, is common in
settings such as hospitals and nursing homes
and among people with weakened immune
systems. Community Associated MRSA, which
infects otherwise healthy people, is usually
found in settings where there is close contact
among people, such as schools. The death rate
from an MRSA infection ranges from 20–30
percent and survivors are susceptible to
recurrent infections, slower response times
to treatments and longer hospital admissions.
As the principal investigator on a $48,225
grant from the Foundation for Healthy Living,
Dr. Lodise will examine different strains of
Health Care Associated MRSA and determine
against which ones vancomycin, the drug typi-
cally prescribed for treating MRSA, is likely to
be the most effective. He will be assisted in his
work by collaborators from Albany Medical
Center, the Buffalo V.A. Medical Center and
Strong Memorial Hospital in Rochester.
The team will identify different biological mark-
ers within each strain of Health Care Associated
MRSA and study how individual strains respond
to treatment with vancomycin. Ultimately, their
research will help health care professionals make
more informed decisions on the best courses
of treatment for MRSA patients. The study is
believed to be the first of its kind to examine
these types of markers in a statewide fashion.
Sufferers of chronic kidney disease (CKD) are
particularly susceptible to MRSA infections.
Between 1995 and 2002, dialysis centers
reported that the increase in incidences of
MRSA soared from 40 to 76 percent, with
vancomycin-resistant cases more than doubling.
Daptomycin, a new alternative to vancomycin,
may prove more successful in treating MRSA in
patients with CKD. But because drugs behave
differently in the bodies of patients being treat-
ed with dialysis versus healthy adults, it is diffi-
cult to know the appropriate dosing of dapto-
mycin. Without proper dosing guidelines, dialy-
sis patients may be exposed to either excess
medication or inadequate doses.
A $241,717 grant from Cubist Pharmaceuticals
will help Dr. Lodise and co-investigator Darren
Grabe ’95, Pharm.D., an associate professor in
the Department of Pharmacy Practice, study
patients undergoing hemodialysis—a procedure
used by nearly two-thirds of all sufferers of
end-stage kidney disease—and employ mathe-
matical modeling to determine the optimal
dosing requirements of daptomycin.
Dr. Lodise and Dr. Grabe are working together
with Katie Pallotta ’06, Pharm.D., and Nimish
Patel ’06, Pharm.D, from ACPHS, and Chris Hoy,
M.D., and Shari Meola, RN, from the Hortense
and Louis Rubin Dialysis Center, the outpatient
clinic used in the study.
Tackling a Serious Public Health ConcernLodise teams with ACPHS faculty and other collaborators on MRSA research
Dr. Lodise is working with Nimish
Patel ’06 to develop dosing guidelines
for patients with MRSA who are
undergoing dialysis.
There’s a killer on the loose in our hospitals and schools. Dr. Thomas Lodise and researchers at ACPHS and across the country are looking into ways to combat a deadly staph infection.
PrezRepVF 4/15/09 1:38 PM Page 18
ACPHS 2008 // 19
A third antibiotic used to treat MRSA is linezol-
id, but many health care professionals choose
not to prescribe this medication, as it may lead
to Serotonin Syndrome in people who take
antidepressants. The syndrome may result in
changes in mental state, as well as neuromus-
cular disorders and overall body hyperactivity.
Because published data supporting increased
incidence of Serotonin Syndrome among
patients taking both linezolid and antidepres-
sant medications remain sparse, there is some
dispute about whether these drugs will interact
in a manner likely to cause the syndrome.
Patients who might react favorably to linezolid
may be prescribed a less effective course of
treatment to avoid the possibility of negative
side effects.
With a $25,000 grant from Pfizer, Dr. Lodise
will study the probability of linezolid and anti-
depressant drugs reacting in a manner that will
result in Serotonin Syndrome. If a connection
can be found, additional research will be done
to determine if certain patient populations are
at higher risks than oth-
ers for this outcome.
While the presence of
MRSA in health care
environments is not new,
its expansion in commu-
nity settings is a recent
and disturbing development. Outbreaks across
the country have made national headlines, and
the trend shows no sign of abating.
Today, more than half of all skin and soft tissue
infections are caused by MRSA. Most of these
patients are treated with antibiotics in an out-
patient setting, where a drug is typically deliv-
ered intravenously over a period of 10–14 days.
With a $154,656 grant from Cubist
Pharmaceuticals, Dr. Lodise will team with
Leon Cosler ’82, Ph.D., director of the Research
Institute for Health Outcomes at ACPHS, to
review a health claims database of patients treat-
ed for skin and soft tissue infections to examine
the effectiveness of vancomycin, daptotmycin
and linezolid, and determine if one of these med-
ications provides superior outcomes in treating
Community Associated MRSA infections.
“As the number of MRSA cases continues to
multiply across the country, the findings of
these research projects will hopefully help
inform health care professionals on how to
better treat afflicted patients and minimize
their suffering.”
Strains of MRSA (Methicillin-resistant
Staphylo-coccus aureus) bacteria, shown
here dividing, are increasingly resistant
to many antibiotic drugs.
PrezRepVF 4/15/09 1:38 PM Page 19
The work being conducted by Dr. Lopes, with
the assistance of Jaclyn, focuses on the devel-
opment of liquid crystalline phases containing
the anti-cancer drug paclitaxel for the topical
treatment of cancers.
The research is particularly important to Jaclyn
who, as one of the first students to enter enroll
in the College’s new master’s degree program
in Pharmaceutical Sciences (MSPS) this fall,
will pursue her Pharm.D. and MSPS degrees
at ACPHS simultaneously.
“Medical research is something I have always
wanted to do and this will give me more flexi-
bility than a Pharm.D. alone,” Jaclyn says. “My
career goal is to work in the industry, develop-
ing drugs or delivery systems.”
Paclitaxel is a chemotherapeutic agent used
to treat several types of cancer. Though it can
be effective in treating skin cancers, including
Kaposi’s Sarcoma and basal cell carcinoma,
severe side effects have limited its usefulness.
Many HIV/AIDS patients suffer from Kaposi’s,
which is characterized by skin lesions that may
spread to the mouth, gastrointestinal tract and
respiratory tract. Presently, the disease is treat-
ed intravenously with paclitaxel with resultant
side effects such as low platelet count, hair loss
and joint pain. Hoping to overcome the drug’s
limitations, Jaclyn is assisting Dr. Lopes in
developing strategies to deliver paclitaxel
directly to the skin, and only the skin, via a
liquid crystalline phase, as this may optimize
drug localization within skin lesions while
eliminating the adverse effects.
“We are currently developing liquid crystalline
systems to enhance the penetration and local-
ization of paclitaxel in the skin while reducing its
transdermal delivery,” says Dr. Lopes. “Liquid crys-
talline phases consist of the state of matter whose
properties are intermediate between a crystalline
solid and a liquid. They look similar to gels, but
they have a very organized internal structure.”
“It doesn’t look like much, but when you get it
under a microscope, it looks really cool,” adds
Jaclyn. “If we can treat the cancer topically and
just get the drug to stay on the skin, we may
be able to significantly reduce the side effects.”
Jaclyn, who has worked with Dr. Lopes over
the past two academic years, says that there
is not much in the literature about the topical
use of paclitaxel. Her role in their pioneering
research currently involves in vitro studies
utilizing the skin from pigs’ ears; she then
measures the results using high-performance
liquid chromatography.
Typically, Jaclyn spends about 10 hours per
week in the lab, working on experiments either
with her mentor or by herself. This summer, the
team will commence in vivo research with rats.
Eventually Jaclyn says their work may focus on
attaching paclitaxel to peptides to deliver the
drug directly to the tumor site.
Last April, Jaclyn made a poster presentation,
which was considered for an award, at the
11th Annual American Association of
Pharmaceutical Scientists Northeast Regional
Discussion Group. The team recently submitted
an abstract to the Annual Meeting of the
Controlled Release Society, which will take
place in Copenhagen this July, and are hoping
to present there as well.
“Jackie is very smart and learns things very
fast,” Dr. Lopes says. “She is focused, commit-
ted and hard-working—qualities which will
allow her to excel in her professional life and
become an outstanding scientist!”
Assistant Professor Luciana Lopes and student Jaclyn Hosmer
are working to develop liquid crystalline systems to enhance the
effectiveness of the anti-cancer drug paclitaxel.
Third-year Pharm.D. student Jaclyn Hosmer ’12 has teamed with Assistant ProfessorLuciana Lopes in groundbreaking research that will hopefully lead to a new treatment—with fewer negative side effects—for various types of skin cancer.
Liquid crystalline phases
observed under a polarized
light mircoscope.
Skin deepTopical treatment offers new possibility for delivering anti-cancer drugs
Lamellar phase Hexagonal phase
PrezRepVF 4/15/09 1:38 PM Page 20
ACPHS 2008 // 21
PrezRepVF 4/15/09 1:40 PM Page 21
SCIENTIF IC METHOD
Enrichment Programs Inspire Next Generation of Scientists
Taylor Lanoue of Averill Park High School performs
a research experiment at PRI while Berne-Knox-Westerlo
student Justin Coon compiles the results.
Dr. Shaker Mousa, executive vice president and chairman of the Pharmaceutical Research
Institute at Albany College of Pharmacy and Health Sciences, in the lab with students Sabith
Choudhury of Hudson High School and Elizabeth Derderian of Averill Park High School.
PrezRepVF 4/15/09 1:41 PM Page 22
ACPHS 2008 // 23
The College now offers three science enrich-
ment programs for students ranging from third
grade to seniors in high school. The newest of
these programs is the High School Research
Program which takes place throughout the
school year at the College’s Pharmaceutical
Research Institute (PRI).
This year, PRI will host more than 40 seniors
from 11 high schools across the Capital Region.
Shaker Mousa, Ph.D., executive vice president
and chairman of PRI, explains that shortly after
the Institute was founded in 2003, he began to
receive requests from friends and colleagues
who were interested in having their sons and
daughters participate in research at the
Institute. He happily obliged, and before long,
word began to spread among students and
teachers at high schools across the region
about this unique opportunity to work under
the direction of accomplished investigators.
“When schools contact me and say they are
looking to place students at PRI, I can’t say no.
I would feel miserable if I turned away some-
one who was interested in science. The child
that I turn away might be the one who finds a
cure to a disease and saves thousands of lives.”
says Dr. Mousa.
Depending on the individual school, students in
the research program are at PRI for six hours
per week for six weeks or four hours per week
for eight weeks. On the first day, Dr. Mousa
meets with them to discuss the parameters of
their projects, which may involve experimenting
with various types of medicines to compare their
effectiveness. Working in pairs, students spend
the first week orienting themselves to the labs
and learning basic research methodologies
before starting their projects. Students are
taught to work independently after the first
week, though research manager Majde Takieddin
remains nearby to supervise their activities,
answer questions and monitor their progress.
During the course of these sessions, they are
expected to gather, graph and analyze their
research data. In June, all of the students return
to PRI to formally present their findings to an
audience comprised of their parents, teachers
and peers.
“Many parents watch in disbelief as their chil-
dren present and defend their research,” says
Dr. Mousa. “They tell me, ’I can’t believe that
those words came from my child’s mouth!’”
Some of the students feel the same way. “I defi-
nitely didn’t think I could do this at the begin-
ning of the year,” said Andrea Nero, a student in
2007–08 program. “If I had seen the poster I
created, I would have thought that I could
never do something like that. But it is possible.”
The forerunner to the PRI program is the High
School Summer Research Program, an annual
program which marked its tenth year at ACPHS
this past summer. The program, in which rising
high school juniors and seniors pursue research
on campus, is overseen by David Clarke, Ph.D.,
chair of the Department of Arts and Sciences.
Five students from Albany and Troy High
Schools were selected to participate in the
2008 session.
In addition to the daily research activities, the
six-week program features “field trips” to sci-
ence and technology facilities such as Albany
Medical Center, Albany Molecular, Regeneron
and Mallinckrodt. ACPHS faculty assisting with
this year’s program included Dr. Mousa as well
as Carlton Campbell, Ph.D., Leon Cosler, Ph.D.,
Martha Hass, Ph.D., Luciana Lopes, Ph.D.,
Abdelhadi Rebbaa , Ph.D. and HaiAn Zheng,
Pharm.D.
As with the PRI program, students in the
summer program must present their research
to a gathering of faculty and staff and answer
questions related to their findings and
methodologies.
“Through the participation of numerous ACPHS
faculty and students as well as the cooperation
of local companies, the Summer Research pro-
gram is able to showcase the many opportuni-
ties available to students in the world of scien-
tific research. Without this type of exposure, it
is difficult for young people to understand the
range of exciting careers in the sciences,” says
Dr. Clarke.
At the opposite end of the age spectrum is the
ACPHS Academy program, which offers a
mathematic and scientific enrichment program
for local, at-risk students beginning in the third
grade and continuing through high school.
The program is designed to encourage stu-
dents at an early age to succeed and to build
confidence academically, particularly in math
and science. Reciprocally, ACPHS students ben-
efit by serving as mentors to these children, an
experience which helps enrich their overall edu-
cation and professional development.
The program was launched in 2006 with a
third-grade class from nearby Delaware
Community School. Students from that class,
now in fifth-grade, are matriculating through
the program, and this year they were joined by
a new class of third-graders from the Brighter
Choice Charter School. The participation of stu-
dents from Brighter Choice was made possible
through a gift of $250,000 from Thomas
D’Ambra, Ph.D., president and CEO of Albany
Molecular Research, and his wife, Connie.
The importance and need to fund these pro-
grams and others like them cannot be overstated.
“There is a crisis that exists in the U.S. when it
comes to getting young people interested in
science and technology. This is the greatest
country when it comes to technology, but we
are in a major decline, while countries such as
China and India are on the rise,” says Dr. Mousa.
“If we lose on science and technology, what is
left for us? We don’t want to reach that level.”
Albany College of Pharmacy and Health Sciences believes stronglythat part of its responsibility as an institution of higher learning isto foster and develop an interest in science among children.
PrezRepVF 4/15/09 1:41 PM Page 23
Each summer, the Student Summer Research
Award Program at Albany College of Pharmacy
and Health Sciences awards internships that
provide a $2,000 stipend and free dormitory
housing to students in any of the degree pro-
grams at the College. This past summer, 10
students participated in the highly competitive,
eight-week program.
An awards ceremony held on October 3, during
Family Weekend, allowed members of the
ACPHS community and parents an opportunity
to see research presentations from participat-
ing students.
Leona Blustein, a sixth-year student, worked
with faculty mentor Sara Dugan, Pharm.D., to
do an assessment of substance use and abuse
among pharmacy students. Faculty members
Nicole Lodise and Jen Cerulli also assisted.
Leona, who hopes to do a general residency
or fellowship in psychiatry after earning her
Pharm.D., found that pharmacists are often
poorly trained to deal with alcohol and drug
abuse, and there is a need for more education
in this area.
Amanda Dihmess and Tom Lodise, Pharm.D.,
worked together on the molecular and clinical
epidemiology of carbapenem-resistant enter-
obacteriaceae. Carbapenems are a mainstay
in therapy against infections caused by gram-
negative bacteria. Amanda hopes to publish
her findings in the spring.
Third-year student Jaclyn Hosmer teamed with
Luciana Lopes, Pharm.D., Ph.D., on the develop-
ment of microemulsions containing paclitaxel
for the topical treatment of Kaposi’s Sarcoma, a
herpes virus-associated cancer. Many HIV/AIDS
patients suffer from Kaposi’s, presently treated
intravenously with resultant side effects (see
article page 20).
Elaine Liu worked with Alexandre Steiner,
Pharm.D., Ph.D., to research what happens
with a shift from fever to hypothermia during
Systemic Inflammatory Response Syndrome,
which can lead to multiple organ failure and death.
Fourth-year student Neil Mandalaywala contin-
ued work he had done during past summers
on Vitamin D-Up Regulated Protein. This time
he studied the role of VDUP-1 in tumor growth,
angiogenesis and metastasis at the
Pharmaceutical Research Institute alongside
Shaker Mousa, Ph.D., MBA.
Anjoli Punjabi and mentor Arnold Johnson,
Ph.D., did research at the V.A. Medical Center
in Albany on preventing septic shock as it
relates to the lungs, in particular studying the
role of tumor necrosis factor.
For the third summer in a row, Alexandra
Rehfuss ’09, who will earn her B.S. in
Pharmaceutical Sciences in May, focused
her work with Robert Levin, Ph.D., on the
treatment of interstitial cystitis and inconti-
nence in women.
Lastly, Peter Youssef presented on his work
with Martha Hass, Ph.D. Peter used his back-
ground in chemistry and developed a project
to analyze phospholipids not just qualitatively
but, for the first time, quantitatively.
Two ACPHS students, Tasmina Hydery ’10 and
Alex Villanueva ’09, have been awarded
American Foundation for Pharmacy Education
(AFPE) “Gateway to Research” Scholarships to
conduct research with Department of
Pharmaceutical Sciences faculty for the
2008–09 academic year. Considering that only
15 awards were given by AFPE nationwide, the
fact that two were granted to ACPHS students
speaks highly of the caliber of research being
done by these students in conjunction with
their faculty mentors.
Tasmina is working with mentor Robert Levin,
Ph.D. on a project entitled “Mechanism of the
protective effect of coenzyme Q10 and alpha
lipoic acid on obstructive urinary bladder dys-
function.
According to Dr. Levin, more than 60 percent
of all men over the age of 50 will develop weak
bladders as the result of an enlarged prostate,
which causes reduced blood flow to the blad-
der and the release of free radicals that dam-
age bladder muscle. Working with rabbits,
Tasmina’s research will try to determine if spe-
cific antioxidants will prevent the development
of weak bladders.
Alex has conducted research with Carlos
Feleder, Ph.D., on elucidating the role of endo-
cannabinoids in septic shock, which results in
an estimated 200,000 deaths each year in the
U.S. alone. Together they have discovered that
administration of Rimonabant, a cannabinoid
receptor antagonist, prior to administration of
shock-inducing lipopolysaccharide (LPS) blocks
shock-related hypotension.
Gateway to Research Scholarships provide out-
standing Pharm.D. students and undergraduates
in other science disciplines with support for a
faculty supervised research experience. The
program strives to attract the most talented stu-
dents to graduate study in the pharmaceutical
sciences by offering a rewarding undergraduate
research experience that includes a $4,000
stipend and $1,000 for supplies.
For more information on the program, visit
http://www.afpenet.org/
Awards Program RecognizesStudent Research
Gateway to ResearchSTUDENTS RECEIVE
PREST IG IOUS
SCHOLARSHIPS
STUDENT RESEARCH
PrezRepVF 4/15/09 1:41 PM Page 24
ACPHS 2008 // 25
Native American studies are not generally the
first thing that comes to mind when thinking of
ACPHS. But a series of electives taken through
the Department of Arts and Sciences at the
College were influential in Philip Lubanski’s
decision to undertake an ambulatory care rota-
tion in the Navajo Nation.
Phil spent a month with the tribe last summer
at the Chinle Comprehensive Health Care
Facility (CCHCF) located on the Navajo Indian
Reservation in Arizona. Before embarking on
his Advanced Pharmacy Practice Experience,
the sixth-year Pharm.D. student took nearly all
of the College’s courses on Native Americans,
including one on Southwestern American Indians.
“These electives are what really sparked my
interest in the rotation,” Phil explains. “Learning
about the culture and actually living on the
reservation are two totally different things, but
Dr. [J. Daniel] d’Oney was very helpful in teach-
ing me about Navajo traditions and important
landmarks located near Chinle.”
The reservation, in the northeast corner of Arizona,
encompasses the famed Canyon de Chelly, site of
ancient Native American ruins and now home
to a living community of Navajo people.
“The Navajo really pride themselves on holding
on to their culture and language,” says Phil.
“Many of the patients I encountered there
spoke little or no English. For others, English
was their second language.”
Phil was assigned to the CCHCF, a part of the
Navajo Area Indian Health Service (IHS). A 60-
bed hospital, the facility serves as a health care
hub for the region. The pharmacy rotation has
accommodated a steady stream of ACPHS stu-
dents, says Director of Experiential Education
Laurie Briceland, Pharm.D., who was instrumen-
tal in establishing the practice site about 15
years ago.
“There are no ’traditional’ pharmacies on the
reservation, just a grocery store that sells some
common over-the-counter medications,” Phil
says. “The only pharmacies are in the IHS hospi-
tals and outpatient clinics. Most Navajo people
get all of their medications from the hospital,
including OTC medications like non-steroidal
anti-inflammatory drugs (NSAIDs).”
Phil’s primary responsibility at the clinic
was counseling, predominantly in the areas
of NSAIDs, antibiotic use and diabetes, the
most common medical problem faced by
the Navajo people.
“Diabetes is a huge issue on the reservation
and one that the IHS is working very hard to
get under control,” Phil explains. “By controlling
patients’ blood sugars, we can prevent further
complications down the road, such as neu-
ropathies, blindness and nephropathy.”
“Counseling really allowed a lot of interaction
with the Navajo people,” he adds. “Many folks
don’t have televisions, cable, internet access or
even newspapers, so the counseling they get at
the clinic is really all that many of them know
about their medications.”
There were several cultural differences Phil had
to be aware of when working with the tribe.
“The Navajo don’t speak of the deceased, so
[when taking a medical history] it is important
to look at a patient’s chart before asking about
their parents or grandparents, to make sure
that they haven’t passed away.”
He also had to be careful when explaining the
side effects of medications as many Navajo
believe that stating that something may hap-
pen in the future will cause the event to occur.
The hospital itself also differs from its off-reser-
vation counterparts. The CCHCF employs tradi-
tional healers for patients who request a Navajo
ceremony, which is then performed in a tradi-
tional Navajo building or ’hogan’ that is located
right on the hospital grounds.
“It was pretty neat trying to convey medication
information across cultural and educational bar-
riers. At times it was a bit challenging, but I
have not experienced a reward professionally
that rivals the feeling of knowing that you have
just taught someone something about their
medications or disease state that they couldn’t
have gotten anywhere else.”
Reservation Rotation Philip Lubanski ’09 Gains Experience in the Navajo Nation
The Navajo Indian Reservation encompasses Canyon de Chelly.
PrezRepVF 4/15/09 1:41 PM Page 25
ASSETS
Cash and cash equivalents $ 14,801,492
Investments 10,586,516
Other assets 3,389,866
Accounts receivable—students 425,919
Receivables—government entities 1,583,276
Other receivables 539,782
Pledges receivable 1,145,057
Student loans receivable 2,391,585
Agency funds 200,958
Deposits with bond trustees 1,552,475
Property, plant & equipment—Net 45,602,328
Total assets $ 82,219,254
LIABILITIES AND NET ASSETS
Liabilities
Line of credit $ 0
Accounts payable and accrued liabilities 895,967
Deferred income and deposits 8,539,234
U.S. government grants refundable 2,133,125
Bonds payable 29,700,776
Capital lease obligation 0
Expected post retirement benefit obligation 830,251
Deposits held in custody for others 200,958
Total liabilities $ 42,300,311
Net Assets
UNRESTRICTED
For current operations $ 2,329,399
Funds functioning as an endowment 4,602,824
Designated for plant capital 7,000,000
Plant fund 19,585,915
Total unrestricted net assets $ 33,518,138
TEMPORARILY RESTRICTED
Unexpended funds received for restricted purposes $ 1,768,115
Total temporarily restricted net assets $ 1,768,115
PERMANENTLY RESTRICTED
Endowment funds $ 4,598,365
O’Brien Loan Fund 34,325
Total permanently restricted net assets 4,632,690
Total net assets 39,918,943
Total liabilities and net assets $ 82,219,254
BALANCE SHEET
Financials
PrezRepVF 4/15/09 1:41 PM Page 26
RevenuesStudent Tuition and Fees 75.03%Government Contracts and Grants 8.43%Gifts and Pledges 4.86%Investment income 0.93%Postgraduate Education 0.30%Other Sources 1.65%Auxiliary Enterprises 8.80%100.00%
Expenses General Administration 17.48%Research 10.86%Student Financial Aid 1.46%Physical Plant 26.68%Institutional Advancement 3.94%Postgraduate Education 0.44%Investment losses 1.76%Instruction/Student Services 37.38%100.00%
ACPHS 2008 // 27
RevenuesStudent Tuition and Fees 75.03%Government Contracts and Grants 8.43%Gifts and Pledges 4.86%Investment income 0.93%Postgraduate Education 0.30%Other Sources 1.65%Auxiliary Enterprises 8.80%100.00%
Expenses General Administration 17.48%Research 10.86%Student Financial Aid 1.46%Physical Plant 26.68%Institutional Advancement 3.94%Postgraduate Education 0.44%Investment losses 1.76%Instruction/Student Services 37.38%100.00%
Government Contracts and Grants 8.43%
Auxiliary Enterprises 8.80%
Other Sources 1.65%
Postgraduate Education 0.30%
Investment Income 0.93%
Gifts and Pledges 4.86%
Student Tuition and Fees 75.03%
REVENUES
EXPENSES
General Administration 17.48%
Research 10.86%
Student Financial Aid 1.46%
Physical Plant 26.68%
Postgraduate Education 0.44%
Investment Losses 1.76%
Instruction/Student Services 37.38%
Institutional Advancement 3.94%
PrezRepVF 4/23/09 2:24 PM Page 27
SCHOLARLY ACTIV ITY
PrezRepVF 4/15/09 1:41 PM Page 28
ACPHS 2008 // 29
PUBLICATIONS
Chu F, Chou P, Mirkin BL, Mousa SA and RebbaaA. Cellular conditioning with Trichostatin Aenhances the anti-stress response through up-regulation of HDAC4 and down-regulation of theIGF/AKT pathway. Aging Cell, May 16, 2008 [Epubahead of print].
Al Sayegh FA Dr, Almahmeed W, Marashi M, BahrA, Mahdi HA, Bakir S, Alhumood S, Farhan MAand Mousa S. Global risk profile verification inpatients with venous thromboembolism inArabian Gulf Countries. Clinical and AppliedThrombosis/Hemostasis, April 8, 2008 [Epubahead of print].
Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA.Novel function of the thyroid hormone analogtetraiodothyroacetic acid: a cancer chemosensi-tizing and anti-cancer agent. Angiogenesis, April4, 2008 [Epub ahead of print].
Fares RR, Lansing LS, Gallati CA and Mousa SA.Antiplatelet therapy with clopidogrel and aspirinin vascular diseases: Clinical evidence for andagainst the combination. Expert Opinion onPharmacotherapy 9(3):377-86, February 2008.
Alsayegh F, Fakeir A, Alhumood S, Abdumalek K,Matar H, Samaul I, Nampoory N, Kabalawi H andMousa S. Use of recombinant activated factor VIIto arrest uncontrolled bleeding: A case series.Clinical and Applied Thrombosis/Hemostasis,Dec 26, 2007 [Epub ahead of print].
Mousa SA. Cell adhesion molecules: potentialtherapeutic & diagnostic implications. MolecularBiotechnology 38(1):33-40, January 2008.
Santulli RJ, Kinney WA, Ghosh S, Decorte BL, LiuL, Tuman RW, Zhou Z, Huebert N, Bursell SE,Clermont AC, Grant MB, Shaw LC, Mousa SA,Galemmo RA Jr, Johnson DL, Maryanoff BE andDamiano BP. Studies with an orally bioavailablealpha V integrin antagonist in animal models ofocular vasculopathy: retinal neovascularization inmice and retinal vascular permeability in diabeticrats. The Journal of Pharmacology andExperimental Therapeutics. 324 (3):894-901,March 2008.
Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’ConnorLJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HYand Davis PJ. Tetraiodothyroacetic acid, a smallmolecule integrin ligand, blocks angiogenesisinduced by vascular endothelial growth factorand basic fibroblast growth factor. Angiogenesis11(2):183-90, 2008.
Mousa SA, Zhang F, Aljada A, Chaturvedi S,Takieddin M, Zhang H, Chi L, Castelli MC,Friedman K, Goldberg MM and Linhardt RJ.Pharmacokinetics and pharmacodynamics of oralheparin solid dosage form in healthy human sub-jects. Journal of Clinical Pharmacology47(12):1508-20, December 2007.
Amirkhosravi A, Meyer T, Amaya M, Davila M,Mousa SA, Robson T and Francis JL. The role oftissue factor pathway inhibitor in tumor growthand metastasis. Seminars in Thrombosis andHemostasis 33(7):643-52, October 2007.
Mousa SA, Bharali DJ and Armstrong D. Fromnutraceuticals to pharmaceuticals to nanophar-maceuticals: A case study in angiogenesis modu-lation during oxidative stress. MolecularBiotechnology 37(1):72-80, September 2007.
Qari MH, Aljaouni SK, Alardawi MS, Fatani H,Alsayes FM, Zografos P, Alsaigh M, Alalfi A,Alamin M, Gadi A and Mousa SA. Reduction ofpainful vaso-occlusive crisis of sickle cell anaemiaby tinzaparin in a double-blind randomized trial.Thrombosis and Haemostasis 98(2):392-6,August 2007.
Bharali DJ, Mousa SA and Thanavala Y. Micro- andnanoparticle-based vaccines for hepatitis B.Advances in Experimental Medicine and Biology601:415-21, 2007.
Mousa SA. Heparin, low molecular weight heparin,and derivatives in thrombosis, angiogenesis, andinflammation: emerging links. Seminars in Thrombosisand Hemostasis 33(5):524–33, July 2007.
Powell JA Jr. and Mousa SA. Neutrophil-activatingprotein-2- and interleukin-8-mediated angiogene-sis. Journal of Cellular Biochemistry102(2):412–20, October 2007.
Ovsag K, Hydery S and Mousa SA. Preferred druglists: Potential impact on health care economics.Vascular Health and Risk Management4(2):403–413, 2008.
GRANTS AND CONTRACTS
PROJECT: Evaluate the pharmacological activityof SelectX compounds in a panel of in vitro assays
SPONSOR: SelectX
TOTAL GRANT: $15,360
PROJECT PERIOD: 1/07–1/08
PROJECT: Role of 1, 6 Anhydo in Enoxaparin frac-tions in the modulation of endothelial tissue factorpathway inhibitor
SPONSOR: Aventis
TOTAL GRANT: $100,000
PROJECT PERIOD: 6/06–09/07
PROJECT: Evaluations of anti-angiogenesis thy-roid hormone antagonists in cancer models
SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program
TOTAL GRANT: $231,250
PROJECT PERIOD: 9/05–9/07
PROJECT: Assay of iron and sucrose in samples
SPONSOR: Genix Pharma, Ltd.
TOTAL GRANT: $18,964
PROJECT PERIOD: 12/31/06–12/07
PROJECT: Generation of tetrac conjugate poly-mers, physiochemical characterization, and initialstability assessment
SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program
TOTAL GRANT: $125,000
PROJECT PERIOD: 1/06–12/07
PROJECT: Anti-angiogenesis efficacies ofTransMolecular lead TM601
SPONSOR: TransMolecular, Inc.
TOTAL GRANT: $27,300
PROJECT PERIOD: 9/06–12/07
PROJECT: Kininogen in ocular angiogenesis-mediated disorders
SPONSOR: Vascular Vision PharmaceuticalsCo./NIH (Eye Institute and Cancer Institute)
TOTAL GRANT: $100,000
PROJECT PERIOD: 12/06–09/07
PROJECT: Wound healing and haemostatic treat-ment using novel pharmaceutical nanopolymer ornanoparticles formulation of thyroid hormone T4analogs
SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program
TOTAL GRANT: $306,900
PROJECT PERIOD: 4/06–12/07
PROJECT: Tissue factor/VIIa modulation in ocularangiogenesis
SPONSOR: Vascular Vision PharmaceuticalsCo./NIH (Eye Institute and Cancer Institute)
TOTAL GRANT: $100,000
PROJECT PERIOD: 6/06–11/07
PROJECT: Cellular and molecular mechanisms ofTPH in the modulation of complement activationand inflammation
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $54,000
PROJECT PERIOD: 3/06–11/07
PROJECT: Cellular and molecular mechanisms ofTPH in the modulation of complement activationand inflammation (amendment)
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $48,000
PROJECT PERIOD: 3/06–12/07
PROJECT: Neuronal protective effects and mech-anisms of Othera’s OT551 nanoparticles
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $56,000
PROJECT PERIOD: 9/06–12/07
PROJECT: Retinal neovascularization in infantmice in ROP
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $14,400
PROJECT PERIOD: 11/06–12/07
PROJECT: The effect of OT551 on nuclear factor-kB pathway activation
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $91,800
PROJECT PERIOD: 12/06–12/07
PROJECT: Funding for Postdoctoral fellow
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $43,802 per year
PROJECT PERIOD: 03/07–03/09
Pharmaceutical Research Institute
PrezRepVF 4/15/09 1:41 PM Page 29
PROJECT: Reversal of chemotherapy resistancewith Othera analogs
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $81,600
PROJECT PERIOD: 12/06–12/07
PROJECT: Assay of tetrac in plasma samples
SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program
TOTAL GRANT: $79,350
PROJECT PERIOD: 12/06–11/07
PROJECT: In vitro evaluation of platelet activationby the test article in human blood
SPONSOR: Merck & Co., Inc.
TOTAL GRANT: $23,750
PROJECT PERIOD: 2/07–2/08
PROJECT: Anti-angiogenesis and Anti-cancerefficacies and mechanisms of TM601
SPONSOR: Transmolecular, Inc.
TOTAL GRANT: $66,700
PROJECT PERIOD: 2/07–11/07
PROJECT: PK/PD of OT304 and OT551 in ratCarrageenan-induced paw edema model
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $10,080
PROJECT PERIOD: 2/07–8/07
PROJECT: PK and PD evaluations of Othera’s leadcompounds in a Murine model of Endotoxin-induced Cytokine release
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $54,060
PROJECT PERIOD: 2/07–8/07
PROJECT: Evaluation of Othera’s leadCompounds in Murine model of Oxazolone-induced ear edema
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $37,800
PROJECT PERIOD: 2/07–8/07
PROJECT: Cancer and drug associated thrombo-sis
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $78,900
PROJECT PERIOD: 1/07–11/07
PROJECT: OT551 and OT304 nanoparticle formu-lation: Synthesis and characterization.
SPONSOR: Othera Pharmaceuticals, Inc
TOTAL GRANT: $66,000
PROJECT PERIOD: 6/07–5/08
PROJECT: Enhancing the efficacy of chemothera-peutic breast cancer treatment with non-antico-agulant heparin
SPONSOR: U.S. Dept. of Defense Breast CancerResearch Program
TOTAL GRANT: $377,620
PROJECT PERIOD: 4/07–3/09
PROJECT: Role of Pentasaccharide Fondaparinuxversus low molecular weight Heparin in woundhealing (Amended to study role in cancer-associ-ated thrombosis)
SPONSOR: Sanofi-Aventis and GlaxoSmithKline
TOTAL GRANT: $35,700
PROJECT PERIOD: 07/07–06/08
PROJECT: Role of Heparin and Heparin deriva-tives beyond anticoagulation
SPONSOR: Sanofi-Aventis
TOTAL GRANT: $100,000
DATES: 9/04–9/07
PROJECT: Role of Cathepsin inhibitors in angio-genesis and chemoresistance
SPONSOR: NSF-US-EGYPT Exchange Program
TOTAL GRANT: $24,950
DATES: 9/07–8/09
PROJECT: Potent lipid mediators and ischemicheart diseases (Upstate New York TranslationalResearch Network—University of Rochester,Cornell University and PRI at ACPHS)
SPONSOR: Foundation for Healthy Living
TOTAL GRANT: $14,309
DATES: 9/07–8/08
PROJECT: Othera XVII OT 304 effect on growthof doxorubicin resistant MCF7 cells in nude mice
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $49,500
DATES: 10/07–3/08
PROJECT: Othera XVIII-Efficacy of OT-304 inmice Xenograft models using drug-sensitive can-cer cell lines
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $49,500
DATES: 12/08–06/08
PROJECT: In Vitro study on extracorporeal filtra-tion system to remove oxaliplatin from bovineblood
SPONSOR: Delcath Systems
TOTAL GRANT: $155,650
DATES: 12/07–11/08
PROJECT: Othera XVIIII-efficacy of OT-304 ongrowth of matrigel implanted pancreatic, ovarianand glioma cancer cells in nude mice
SPONSOR: Othera Pharmaceuticals, Inc.
TOTAL GRANT: $49,500
DATES: 02/08–09/08
PROJECT: Assay of over-sulfated ChondroitinSulfate in Heparin samples
SPONSOR: Medtronic Inc.
TOTAL GRANT: $50,160
DATES: 4/08–5/08
PROJECT: Anti-angiogenesis efficacy of TM610against various pro-angiogenesis factors
SPONSOR: TransMolecular, Inc.
TOTAL GRANT: $18,150
DATES: 6/08–12/08
PROJECT: Experimental models for testing noveltargets for pancreatic cancer cell invasion
SPONSOR: National Institutes of Health
TOTAL GRANT: $368,445
DATES: 4/08–3/10
PROJECT: Evaluation of the anti-angiogenesisefficacy of Tetrac versus two different Tetracnanoformulations
SPONSOR: Charitable Leadership FoundationMedical Technology Acceleration Program
TOTAL GRANT: $11,220
DATES: 6/3/2008–6/13/2008
ABSTRACTS/PRESENTATIONS
XXIst Congress of the International Society onThrombosis and Haemostasis, Geneva,Switzerland, July 2007 (6 abstracts)
American Cancer Association, San Diego, Calif.,2008 (3 abstracts)
KeyStone Symposia, Breckinridge, Colorado,2008 (1 abstract)
Association for Research in Vision andOpthamology, Fort Lauderdale, Fla., April 2008 (3 abstracts)
7th International Haemostasis, Saudi Arabia, May 2008 (2 abstracts)
American Society of Clinical Oncology, Chicago,Ill., May 2008 (1 abstract)
American Thyroid Society Meeting, June 2008 (1 abstract)
PrezRepVF 4/15/09 1:41 PM Page 30
ACPHS 2008 // 31
PUBLICATIONS
Machaon Bonafede
Bonafede M, Dick A, Noyes K, Klein JD and BrownT. The effect of acupuncture utilization on health-care utilization. Medical Care 46(1):41-8, January2008.
Nicole M. Stack Lodise
Stack NM and Zillich AJ. Implementation of inpa-tient and outpatient tobacco cessation programs.American Journal of Health-system Pharmacy64: 2074-2079, October 2007.
Thomas P. Lodise
Lodise TP, Pypstra R, Kahn JB, Murty BP, KimkoHC, Bush K, Noel G and Drusano GL. Probabilityof target attainment for ceftobiprole as derivedfrom a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents andChemotherapy 51:2378-2387, 2007.
Lodise TP, Miller CD, Patel N, Graves J andMcNutt LA. Identification of patients withPseudomonas aeruginosa respiratory tract infec-tions at greatest risk for carbapenem resistance.Infection Control and Hospital Epidemiology28(8):959–65, August 2007.
McGregor JC, Rich SA, Harris AD, Perencevich EN,Osih R, Lodise TP, Miller RR and Furuno JP. A sys-tematic review of the methods used to assess theassociation between appropriate antibiotic thera-py and mortality in bacteremic patients. ClinicalInfectious Diseases 45(3):329–37, August 2007.
Lodise TP, Kwa A, Cosler LE, Gupta R and SmithRP. Comparison of β-lactam and macrolide com-bination therapy vs. fluoroquinolone monotherapyin hospitalized Veteran Affairs’ patients with com-munity-acquired pneumonia. AntimicrobialAgents and Chemotherapy, August 2007 [Epubahead of print].
Lodise TP, Kinzig-Schippers M, Drusano GL, LoosU, Vogel F, Bulitta J, Hinder M and Sörgel F. Use ofpopulation pharmacokinetic modeling and MonteCarlo simulation to describe the pharmacody-namic profile of cefditoren in plasma and epithe-lial lining fluid. Antimicrobial Agents andChemotherapy 52(6):1945-51, June 2008.
Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RNand Sörgel F. Pharmacodynamics of ceftazidimeand meropenem in cerebrospinal fluid: Results ofpopulation pharmacokinetic modeling and MonteCarlo Simulation. Journal AntimicrobialChemotherapy 60:1038–44, November 2007.
Lodise TP, Patel N, Graves J, Kwa A, Furuno JP,Graffunder E, Lomaestro BM and McGregor JC.Predictors of 30-day mortality among patientswith Pseudomonas aeruginosa bloodstreaminfections: The impact of delayed appropriateantibiotic selection. Antimicrobial Agents andChemotherapy 51(10):3510–5, October 2007.
Lodise TP, McKinnon PS, Levine DP and RybakMJ. Impact of empirical therapy selection on out-comes of intravenous drug users with Methicillinsusceptible Staphylococcus aureus infectiveendocarditis. Antimicrobial Agents andChemotherapy 51(10):3731-3, October 2007.
Lodise TP, Nau R, Kinzig M, Jones RN and SörgelF. Comparison of the probability of target attain-ment between Ceftriaxone and Cefepime in thecerebrospinal fluid and plasma againstStreptococcus pneumoniae. DiagnosticMicrobiology and Infectious Disease58(4):445–52, August 2007.
Lodise TP and McKinnon PS. Outcomes and eco-nomic considerations with serious infections dueto Methicillin resistant Staphylococcus aureus.Pharmacotherapy 27(7):1001–12, July 2007.
Miller CD, El-Kholi R, Faragon J and Lodise TP.Prevalence and risk factors for clinically significantdrug interactions with antiretroviral therapy.Pharmacotherapy 27(10)1379–1386, 2007.
Lodise TP, Gotfried M, Barriere S and Drusano GL.Telavancin penetration into human epithelial liningfluid as determined by population pharmacokinet-ic modeling and Monte Carlo Simulation.Antimicrobial Agents and Chemotherapy, April2008 [Epub ahead of print].
Lodise TP, Lomaestro BM, Graves J and DrusanoGL. Larger Vancomycin doses are associated withan increased incidence of nephrotoxicity.Antimicrobial Agents and Chemotherapy 52(4);1330–6, April 2008.
Mohr JF, Peymann PJ, Troxell E, Lodise TP andOstrosky-Zeichner L. Risk factors for hyper-glycemia in hospitalized adults receivingGatifloxacin: A retrospective, nested case-con-trolled analysis. Clinical Therapeutics 30(1):152–7,January 2008.
Bhat SV, Peleg AY, Lodise TP, Shutt KA, CapitanoB, Potoski BA and Paterson DL. Failure of currentcefepime breakpoints to predict clinical outcomesfrom Gram negative bacteremia. AntimicrobialAgents and Chemotherapy 51(12):4390–5,December 2007.
Lodise TP, Patel N, Renaud-Mutart A, GorodeckyE, Fritsche TR and Jones RN. Pharmacokineticand pharmacodynamic profile of Ceftobiprole.Diagnostic Microbiology and Infectious Diseases61(1):96-102, May 2008.
Lodise TP and Neuhauser M. Community-associ-ated Methicillin-resistant Staphylococcus aureusin Pharmacotherapy Self-Assessment Program,Sixth Edition, Infectious Diseases (Dunsworth T,Richardson M, Chant C, Cheng JWM, ChessmanKH, Hume AL, et al, eds.), Lenexa, Kan.: AmericanCollege of Clinical Pharmacy, 37–54, 2008.
Lodise TP, Lomaestro BM and Drusano GL.Practical Application of pharmacodynamic princi-ples to optimize therapy and treat resistantorganisms: A focus on Beta-Lactam antibiotics inAntimicrobial Resistance: Problem Pathogensand Clinical Countermeasures (Owens RC andLautenbach E, eds.), New York, N.Y.: InformaHealthcare USA, Inc., 317–335, 2008.
McKinnon PS and Lodise TP. Outcomes and costconsiderations with MRSA infections. in MRSA(Weigelt J, ed.), New York, N.Y.: InformaHealthcare USA, Inc., 189–211, 2008.
Patel N, McNutt LA and Lodise TP. The relation-ship between varying prior antibiotic exposuredefinitions and piperacillin/tazobactam resistanceamong patients with Pseudomonas aeruginosarespiratory tract infections. Antimicrobial Agentsand Chemotherapy, June 2008 [Epub ahead ofprint].
Teresa J. Lubowski
Lubowski TJ, Cronin LM, Pavelka R., Briscoe-Dwyer L. and Hamilton RA. A medication recon-ciliation project conducted by Pharm. D. studentsduring an APPE in a multi-site health system.American Journal of Pharmaceutical Education71 (5): Article 94, 2007.
Margaret Malone
Malone M. The obesity pandemic: How did we gethere? The Annals of Pharmacotherapy 41:1497–8,2007.
Cerulli J and Malone M. Women’s health promo-tion within a community advanced pharmacypractice experience. American Journal ofPharmaceutical Education 72(2):Article 25, 2008.
Alger-Mayer S, Polimeni J and Malone M. Pre-operative weight loss as a predictor of long termsuccess following Roux-en-Y gastric bypass.Obesity Surgery, April 2008 [Epub ahead of print].
Alger-Mayer S. Rosati C, Polimeni J and MaloneM. Pre-operative binge eating status and gastricbypass surgery. Obesity Surgery, May 2008[Epub ahead of print].
John M. Polimeni
Polimeni JM. Assessment of the economics cur-riculum at a college of pharmacy. Journal ofCollege Teaching and Learning 4(10):47–56,October 2007.
Polimeni JM and Polimeni RI. Energy consumptionin transitional economies (Part I): Jevons’ Paradoxfor Romania, Bulgaria, Hungary and Poland.Romanian Journal of Economic Forecasting4(3):63-80, September 2007.
Polimeni RI and Polimeni JM. Multi-scale integrat-ed analysis of societal metabolism and Jevons’Paradox for Romania, Bulgaria, Hungary andPoland (Part II). Romanian Journal of EconomicForecasting 4(4):61–76, December 2007.
Onyeiwu S, Polimeni RI and Polimeni JM.Distributional impact of globalization-inducedmigration: Evidence from a Nigerian Village.WIDER Research Paper 66, October 2007.
Onyeiwu S, Polimeni RI and Polimeni JM.Distributional impact of globalization-inducedmigration: Evidence from a Nigerian Village.African Development Review 20(1):115–34, April2008.
Polimeni JM. Jevons’ Paradox: A case study ofChina. International Journal of InterdisciplinarySocial Sciences 2(2): 383–394, 2007.
Polimeni RI and Polimeni JM. Structural adjust-ment and the Igbo extended family. InternationalJournal of the Humanities 5(4):77-82, 2007.
Polimeni RI and Polimeni JM. Multi-scale integrat-ed analysis of societal metabolism: The case ofRomania. International Journal ofInterdisciplinary Social Sciences 2(2):41–51, 2007.
Polimeni JM. Protecting the global food supplyfrom a terrorist attack. International Journal ofthe Humanities 5(4):71–75, 2007.
Polimeni JM. Assessment of the economics cur-riculum at a college of pharmacy. Journal ofCollege Teaching & Learning, 4(10):47–56, 2007.
Polimeni JM. Jevons’ Paradox and the economicimplications for Europe. International Businessand Economics Research Journal, 6(10):109–119,2007.
Polimeni JM, Mayumi K, Giampietro M and AlcottB. The Jevons’ Paradox: The Myth of ResourceEfficiency Improvements. London, U.K: EarthscanPublications, Ltd., January 2008.
Pharmacy Practice
PrezRepVF 4/15/09 1:41 PM Page 31
ABSTRACTS/PRESENTATIONS
Machaon Bondafede
Guilbert T, Schatz M, Davis EA, Tomaszewski KJand Bonafede M. Health care utilization is higheramong patients whose asthma is not well-con-trolled: Evidence from a large longitudinal cohort.American Academy of Allergy Asthma andImmunology Annual Meeting, Philadelphia, Pa.,March 2008.
Garris C, Schatz M, Guilbert T, Davis EA, Bonus Tand Bonafede M. Asthma control is predictive ofhealth-related quality of life: Survey using theAsthma Control Test™ and Childhood AsthmaControl Test™. American Academy of AllergyAsthma and Immunology Annual Meeting,Philadelphia, Pa., March 2008.
Michael R. Brodeur
Brodeur MR. Medications and older adults with afocus on dysphagia. New York State DisabilityServices and Organizations, Syracuse N.Y.,September 2007.
Brodeur MR. Anticholinergic medications andolder adults. Continuing Education Program,Albany College of Pharmacy, Albany, N.Y.,September 2007.
Brodeur MR. Diphenhydramine and tetracaine.Colonie Emergency Medical Services, Albany, N.Y.,September 2007.
Brodeur MR and Pannenton K. Anticholinergicmedications. Island Peer Review Organization(IPRO) Teleconference, New York State,November 2007.
Brodeur MR. Naloxone. Colonie EmergencyMedical Services, Albany, N.Y., January 2008.
Brodeur MR and Saffel D. Proton pump inhibitors:Point, counterpoint. American Medical DirectorsAssociation, Salt Lake City, Utah, March 2008.
Jennifer Cerulli
Cerulli J. Community pharmacy practice initiativeto support the identification and education ofpeople with Chronic Obstructive PulmonaryDisease. American Pharmacists Association 2008Annual Meeting and Exposition, San Diego, Calif.,March 2008.
Angela C. Dominelli
Bruce SP, Schwartz A and Dominelli A. Survey ofcurricular changes. Annual Meeting of theAmerican Association of Colleges of Pharmacy,Orlando, Fla., July 2007.
Gina D. Garrison
Garrison GD, Strang AF, Rivers S and LubowskiTJ. A pharmacy student based coronary heart dis-ease (CHD) risk assessment service in the ambu-latory care setting: Patient and student outcomes.American Association of Colleges of PharmacyAnnual Meeting, Orlando, Fla., July 2007.
Garrison GD. Pharmaceutical industry influence atan academic medical center. Department ofMedicine Grand Rounds, Albany Medical Center,Albany, N.Y., September 2007.
Garrison GD. Dyknow educational technology usein the large or small classroom: Sharing the expe-rience. Fall 2007 Capital District EducationalTechnology Group Conference, Albany College ofPharmacy, Albany, N.Y., October 2007.
Garrison GD. Cardiovascular risk factors.Continuing Education program, PharmacistsSociety of the State of New York Mid-winterConference, Saratoga Springs, N.Y., January 2008.
Garrison GD. Ties that bind: Professional relation-ships with pharmaceutical industry. PharmacyPractice Institute, Albany College of Pharmacy,Albany, N.Y., March 2008.
Garrison GD. Ties that bind: Professional relation-ships with industry. St. Peters Hospital MedicalGrand Rounds, Albany, N.Y., April 2008.
Garrison GD. Keynote address. Beta Theta chap-ter induction, Rho Chi Pharmacy Honor Society,Arnold and Marie Schwartz College of Pharmacyand Health Sciences, Long Island University—Brooklyn Campus,. Brooklyn, N.Y., May 2008.
Nicole M. Lodise
Lodise NM. Tobacco cessation in the inpatient set-ting. Greater New York Hospital Association, EastElmhurst, N.Y.,October 2007.
Lodise NM. Nicotine dependence and treatment:A look at the myths and facts. Addiction MedicineInstitute, Albany Medical Center, Albany, N.Y.,November 2007.
Lodise NM. Cervical cancer and the HPV vaccine.Pharmacy in the News Continuing Education pro-gram, Albany College of Pharmacy, Albany, N.Y.,November 2007.
Lodise NM. Tobacco cessation for the busy clini-cian. Albany Medical Center OB/GYN GrandRounds, Albany, N.Y., November 2007.
Lodise NM. How to incorporate tobacco cessationinto a busy setting. New York State Council ofHealth-system Pharmacists Winter Conference,Killington, Vt., January 2008.
Thomas P. Lodise
Lodise TP, Lomaestro BM, Graves J and DrusanoGL. Higher empirical Vancomycin dosing is associ-ated with increased nephrotoxicity. 45th AnnualMeeting of the Infectious Diseases Society ofAmerica, San Diego, Calif., October 2007.
Lodise TP, Graves J, Evans A, Graffunder E,Helmecke M and Stellrecht K. Predictors ofVancomycin treatment failure among patientswith MRSA bacteremia. 45th Annual Meeting ofthe Infectious Diseases Society of America, SanDiego, Calif., October 2007.
Lodise TP, Lomaestro B, Kwa A and Drusano GL.Pharmacodynamics of extended infusionPiperacillin/Tazobactam against Pseudomonasaeruginosa. 45th Annual Meeting of the InfectiousDiseases Society of America, San Diego, Calif.,October 2007.
Helmecke M, Graves J, Evans A, Graffunder E,Stellrecht K and Lodise TP. Predictors ofVancomycin MIC ³ 2 mg/L among patients withMRSA bacteremia. 45th Annual Meeting of theInfectious Diseases Society of America, SanDiego, Calif., October 2007.
Drusano GL, Ambrose PG, Bhavnani SM, LodiseTP, Rubino CM, Forrest A, Louie A and RodvoldKA. Vancomycin dose recommendations for hos-pital-, ventilator- or health care- associated pneu-monia and the attainment of Vancomycin throughconcentrations of 15-20 mg/L: CognitiveDissonance. 45th Annual Meeting of theInfectious Diseases Society of America, SanDiego, Calif., October 2007.
Miller C, El-Kholi R, Lodise TP and Fish D.Virologic and immunologic efficacy ofDidanosine/Tenofovir as a NRTI backbone withinPI-based HAART. 47th Interscience Conferenceon Antimicrobial Agents and Chemotherapy,Chicago, Ill., September 2007.
Patel N, Graffunder E, Evans A, Helmecke M,Stellrecht K and Lodise TP. Relationship betweenhVISA and outcomes among patients with MRSAbloodstream infections treated with Vancomycin.18th European Congress of Clinical Microbiologyand Infectious Diseases, Barcelona, Spain. April2008.
Patel N, Graffunder E, Evans A, Helmecke M,Stellrecht K and Lodise TP. Predictors of hVISAamong patients with MRSA bacteremia. 18thEuropean Congress of Clinical Microbiology andInfectious Diseases, Barcelona, Spain. April 2008.
Patel N and Lodise TP. Predictors of piperacillin-resistant Pseudomonas aeruginosa amongpatients with respiratory tract infections: The pre-dictive value of varying exposure definitions andthe risk of multiple prior antibiotic exposures.18thEuropean Congress of Clinical Microbiology andInfectious Diseases, Barcelona, Spain. April 2008.
Lodise TP. Continuous and short-term infusionstrategies. Making a Difference in InfectiousDiseases Pharmacotherapy Annual Conference,Orlando, Fla., May 2008.
Lodise T. Resistant gram-negative infections: Newtreatment approaches—Improving the outcomewith PK/PD. Making a Difference in InfectiousDiseases Pharmacotherapy Annual Conference,Orlando, Fla., May 2008.
Lodise T. Treatment of MRSA: New and improvedversus old and reliable. Continuing Education pro-gram, Albany College of Pharmacy, Albany, N.Y.,April 2008.
Lodise T. MRSA Update. Continuing Educationprogram, Albany College of Pharmacy, Albany,N.Y., February 2008.
Teresa J. Lubowski
Lubowski TJ and Cerulli J. Quality assurance pro-gram for pharmacy practice experiences usingCAPE-based capabilities checklists. AmericanAssociation of Colleges of Pharmacy, Orlando,Fla., July 2007.
Margaret Malone
Malone M. Altered drug disposition after bariatricsurgery. Treatment options for obesity: Focus ses-sion on bariatric surgery. American College ofClinical Pharmacy Spring Practice and ResearchForum, Phoenix, Ariz., April 2008.
Macary W. Marciniak
Marciniak MW and Malone D. NationalImmunization Awareness Month /APhA-ASPOperation Immunization, Schenectady Today—Wednesday Edition (live interview), August 2007
Marciniak MW. Patient-centered care to minimizecardiovascular risk: How to fit outcomes monitor-ing in the busy community pharmacy practice.Continuing Education Program, Albany College ofPharmacy, Albany, NY, August 2007.
Marciniak MW and Davison L. AmericanPharmacists Month, SchenectadyToday–Wednesday Edition (live interview),October 2007.
PrezRepVF 4/15/09 1:41 PM Page 32
ACPHS 2008 // 33
Marciniak MW. Pharmacist and student pharma-cist perceptions of the self-care championship.Nonprescription Medicines Academy, Cincinnati,Ohio, October 2007.
Marciniak MW. Navigating through the pharmacyresidency process, American PharmacistsAssociation—Academy of Student Pharmacists(APhA-ASP) Midyear Regional Meeting, Denver,Colo., October 2007.
Marciniak MW. Progress report: Providing clinicalpharmacy services in chain pharmacies. AmericanCollege of Clinical Pharmacy Annual Meeting,Denver, Colo., October 2007.
Marciniak MW. The role of pharmacist as immuniz-er. Nassau/Suffolk Adult ImmunizationConference, Melville, N.Y., October 2007.
Marciniak MW. Navigating through the pharmacyresidency process, American PharmacistsAssociation - Academy of Student Pharmacists(APhA-ASP) Midyear Regional Meeting, Albany,N.Y., October 2007.
Marciniak MW. Pharmacists as immunizers. NewYork Chapter of the American College ofPhysicians Scope of Practice Forum, Syracuse,N.Y., October 2007.
Marciniak MW. Immunization and the pharmacist.Albany College of Pharmacy Annual Law Day,Albany, N.Y., November 2007.
Marciniak MW and White L. AmericanPharmacists Association Pharmacy-basedImmunization Delivery Certificate TrainingProgram. Pharmacists Society of the State of NewYork Midwinter Conference, Saratoga Springs,N.Y., January 2008.
Marciniak MW. Medicare Modernization Act: OTCsto get through the gap. Virginia PharmacistsAssociation Mid-Year Conference, Charlottesville,Va., February 2008.
Marciniak MW. Pharmacists as immunizers:Testimony provided on avian influenza and the“Pharmacists as Immunizers” bill. New York CityCouncil Committee on Health, New York, N.Y.,February 2008.
Marciniak MW and Rothholz MC. Immunizationsand the pharmacist. Institute for ContinuingEducation/1199 SEIU League Training andUpgrading Fund, New York, N.Y., March 2008.
Marciniak MW. Medication Therapy Management.Press briefing for the release of MedicationTherapy Management in Pharmacy Practice:Core Elements of an MTM Service Model Version2.0, San Diego, Calif., March 2008.
Marciniak MW. Medication Therapy Management:New help for prescription med questions.Television interview for San Diego NBC, SanDiego, Calif., March 2008.
Marciniak MW. Pharmacists as immunizers.Television interview broadcast toAssemblywoman Amy Paulin’s 88th AssemblyDistrict, Westchester, N.Y., March 2008.
Marciniak MW. Pharmacists administering influen-za and pneumococcal vaccines to adults in NewYork State. Roundtable discussion sponsored byAssemblyperson Deborah Glick, New YorkAcademy of Medicine, New York, N.Y., May 2008.
Christopher D. Miller
Miller CD. Antiretroviral therapy in 2007. KinneyDrug Regional Office, Syracuse, N.Y., September2007.
Miller C. Approach to salvage and treatment-experienced patients with HIV. New York StateDepartment of Corrections, Albany, N.Y., January2008.
Miller C. What’s bugging you? Influenza vaccineand therapy. Annual Pulmonary Update, Albany,N.Y., January 2008.
John M. Polimeni
Polimeni JM. Analysis of medicinal drugs asgroundwater pollutants and a possible solution.Seminar of the School of Doctorate Studies in thePharmacological Sciences, Department ofFarmacology and Anestesiolgy, Universita’ DegliStudi di Padova, September 2007.
Polimeni JM. Institutions and organizations in theEuropean agri-food systems: Economic and soci-ological approaches. Universita’ Degli Studi diPerugia, Facolta’ di Agraria, Perugia, Italy,September 2007.
Polimeni JM, Cosler LE, Chandrasekara R andDobis M. A theoretical approach to reduce dis-carded pharmaceuticals in the environment.Fourth International Conference onEnvironmental, Cultural, Economic and SocialSustainability, Universiti Malaysia, Terengganu,Malaysia, January 2008.
Polimeni J. Structural adjustment, economicdevelopment and vulnerability: Evidence fromtwo Nigerian communities. 34th AnnualConference of the Eastern Economic Association,Boston, Mass., March 2008.
Polimeni J, Dobis M and Cosler LE. A cost-effec-tiveness analysis of a prescription and over-the-counter drug take-back program for New YorkState. 2007 Northeast Water Science Forum,Portland, Me., August 2007.
Polimeni J. Analysis of medicinal drugs as ground-water pollutants and a possible solution. Seminarof the School of Doctorate Studies in thePharmacological Sciences, Universita’ Degli Studidi Padova, Padua, Italy, September 2007.
Aimee F. Strang
Strang A, Bruce SP, Grabe D and Dominelli A.Mapping of pharmacotherapy outcomes: Anassessment-based strategy. Annual Meeting ofthe American Association of Colleges ofPharmacy. Orlando, Fla., July 2007.
Sarah L. Scarpace
Scarpace, SL. Ralox! The FDA approved it! SERMSfor chemoprevention. Barbara DiLascia LectureSeries on Womens’ Health, Albany College ofPharmacy, Albany, N.Y., October 2007.
Scarpace SL. Board Certified OncologyPharmacist presentation on Head/Neck Cancers.Hematology Oncology PharmacistsAssociation/International Society of OncologyPharmacy Practitioners 2008 Conference,Anaheim, Calif., June 2008.
Scarpace SL. Optimizing anti-emetics forchemotherapy-induced nausea/vomiting. ACPContinuing Education program: Annual PharmacyPractice Institute, Albany, NY. March 2008.
Tanya Vadala
Vadala T and Flynn A. NYS Board review. PSSNY,Saratoga Springs, N.Y., January 2008.
GRANTS
Leon E. Cosler
PROJECT: Regional variation in cancer-care treat-ment and outcomes
SPONSOR: ACP Scholarship of Discovery andEducational Excellence Grant
CO-INVESTIGATORS: Sarah Scarpace, MachaonBonafede and Steve Szebenyi
TOTAL GRANT: $15,000
GRANT PERIOD: 2008–2009
Sara E. Dugan
PROJECT: AACP Annual Meeting
SPONSOR: 2008 Wal-Mart Annual ConferenceScholarship Program
CO-AWARDEE: Leona Blustein
TOTAL GRANT: $1,000
Gina Garrison
PROJECT: AACP Annual Meeting
SPONSOR: 2008 Wal-Mart Annual ConferenceScholarship Program
CO-AWARDEE: Whitney Caron
TOTAL GRANT: $1,000
PrezRepVF 4/15/09 1:41 PM Page 33
PUBLICATIONS
Richard E. Dearborn Jr.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM and Dearborn Jr. RE.The tumor suppressor vitamin D3 up-regulatedprotein 1 (VDUP1) functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315(2):489–504, March 2008.
Carlos Feleder
Yilmaz MS, Millington WR and Feleder C. Thepreoptic anterior hypothalamic area mediates thehypotensive response induced by lipopolysaccha-ride in male rats. Shock 29(2):232–7, February2008.
Pallares EM, Shmuckler J, Scacchi P, Feleder Cand Cutrera RA. Effects of prenatal stress onmotor performance and anxiety behavior in swissmice. Physiology and Behavior 92:951–956, 2007.
Gail Goodman Snitkoff
Goodman Snitkoff G. Common infectious diseasesand immunization in Concepts in Immunologyand Immunotherapeutics, 4th Edition (B. Smith,ed.), Bethesda, Md.: American Society of Health-System Pharmacists, 2008.
Goodman Snitkoff G. Immunology inComprehensive Pharmacy Review, 7th Edition (L.Shargel, ed.), Philadelphia: Lippincott, Williamsand Wilkins, 2008.
Goodman Snitkoff G. Microbiology inComprehensive Pharmacy Review, 7th Edition.(L. Shargel, ed.), Philadelphia: Lippincott, Williamsand Wilkins, 2008.
Robert M. Levin
Palmieri K, Mannikarottu AS, Chichester P, KoganB, Leggett RE, Whitbeck C and Levin RM. Theeffects of cyclical estrogen on bladder and ure-thral structure and function. British Journal ofUrology 99:171–176, 2007.
Whitbeck V, Chichester P, Sokol R and Levin RM.Role of nitric oxide in urinary bladder function:Effect of L-Arginine in the presence and absenceof partial outlet obstructions. UrologiaInternationalis 78:30–36, 2007.
Arecht MM, Chichester P, Michel MC and LevinRM. Effect of short-term outlet obstruction on ratbladder nerve density and contractility.Autonomic and Autacoid Pharmacology27:47–53, 2007.
Lin AD, Mannikarottu AS, Kogan BA, Whitbeck C,Leggett RE and Levin RM. Effect of bilateral in-vivo ischemia/reperfusion on the activities ofsuperoxide dismutase and catalase: Response toa standardized grape suspension. Molecular andCellular Biochemistry 296:11–16, 2007.
Agartan CA, Leggett RE, Kogan BA and Levin RM.Effect of age on the response to in-vitro ischemiaof the rabbit bladder. Urologia Internationalis78:155–159, 2007.
Onal B, Levin RM, Kogan BA, Whitbeck C andMannikarottu AS. Effect of maturation and age onestrogen induced functional hypertrophy of thefemale rabbit bladder. BJU International99(3):674-679, March 2007.
Guven A, Whitbeck C, Chichester P, Leggett RE,Kogan BA, Mannikarottu AS and Levin RM. Effectof age on the response to short term partial blad-der outlet obstruction in the rabbit. BJUInternational 100(4):930–934, October 2007.
Juan Y-S, Onal B, Broadway S, Cosgrove J,Leggett RE, Whitbeck C, De E, Sokol R and LevinRM. Effect of castration on male rabbit lower uri-nary tract tissue enzymes. Molecular and CellularBiochemistry 301:227–233, 2007.
Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S,Chichester P, Mannikarottu AS and Levin RM.Effect of Letrozole on female rabbit urinary blad-der function. BJU International 100(6):1391–1395,December 2007.
Lin W-Y, Levin RM, Chichester P, Leggett RE, JuanY-S, Johnson A, Neuman P, Whitbeck C, Guven A,Kogan BA and Mannikarottu AS. Effects of L-Arginine and L-NAME on chronic partial bladderoutlet obstruction in the rabbit. American Journalof Physiology. Regulatory, Integrative andComparative Physiology 293:2390-2399, 2007.
Guven A, Kalorin C, Onal B, Whitbeck C,Chichester P, Kogan BA, Levin RM andMannikarottu AS. Novel biomarkers of bladderdecompensation after partial bladder obstruction.Neurourology and Urodynamics 26:1036–1042,2007.
Juan Y, Lin W, Kalorin C, Kogan B, Levin RM andMannikarottu AS. The effect of partial bladderoutlet obstruction on carbonyl and nitrotyrosinedistribution in rabbit bladder. Urology70:1249–1253, 2007.
Onal B, Levin RM, Kogan BA, Guven A, LeggettRE and Mannikarottu AS. Novel alterations insuperoxide dismutase and catalase activities inthe female rabbit bladder subjected to hormonalmanipulations. International Urology andNephrology 39(4):1049-1054, 2008.
Chou EC, Whitbeck C, Herz J, Demopulos GA andLevin RM. The effect of intravesical ketoprofen onAcetylcholine-evoked urinary bladder contractilityand detrusor overactivity in the anesthetized rab-bit model. International Urology and Nephrology39(4):1055–1059, 2007.
Chou EC, Whitbeck C, Borow A, Burden O, Mays Pand Levin RM. The effect of intravesical ketopro-fen on Ach-evoked urinary bladder contractilityand hyperreflexia in the anesthetized rabbitmodel.
Lin WY, Guven A, Juan YS, Johnson A, Neuman P,Whitbeck C, Chichester P, Kogan B, Levin RM andMannikarottu AS. Free radical damage as a bio-marker of bladder dysfunction after partial outletobstruction and reversal. BJU International101:621–626, 2008.
Levin RM, Juan Y-S, Whitbeck C., Perez-MartinezFC and Lin WY. The effect of Darifenacin on over-active bladder in female and male rabbits.International Urology and Nephrology [EPubahead of print, August 7, 2007].
Guven A, Lin WY, Leggett RE, Kogan BA, LevinRM and Mannikarottu A. Effect of aging on theresponse of biochemical markers in the rabbitsubjected to short-term partial bladder obstruc-tion. Molecular and Cellular Biochemistry306(1–2):213-9, December 2007.
Lin WY, Mannikarottu A, Chichester P, Guven A,Johnson A, Neuman P, Juan YS, Schuler C, KoganBA, and Levin RM. Changes in the smooth muscleof the corpora cavernosum related to reversal ofpartial outlet obstruction in rabbits. Journal ofAndrology 29(2):164–71, Mar–April 2008.
Juan YS, Mannikarottu AS, Hydery T, Lin WY,Kogan BA, Whitbeck C, Leggett RE and Levin RM.Coenzyme Q10 protect against ischemia / reper-fusion induced biochemical and functionalchanges in rabbit urinary bladder. Molecular andCellular Biochemistry 311(1–2):73-80, April 2008.
Lin WY, Rehfuss A, Whitbeck C and Levin RM.Effect of co-enzyme Q10 and α-lipoic acid on theresponse of the rabbit urinary bladder to repeti-tive stimulation and in vitro ischemia. Urology72(1):214–9, 2008.
Arnold Johnson
Gertzberg N, Gurnani T, Neumann P, Forbes AK,Jean-Louis N and Johnson A. Tumor necrosis fac-tor-± (TNF) causes barrier dysfunction mediatedby tyrosine98 and tyrosine218 in β-actin.American Journal of Physiology: Lung Cellularand Molecular Physiology 293(5):L1219–L29,August 2007.
Lin WY, Levin RM, Chichester P, Leggett R, JuanYS, Johnson A, Neumann P, Whitbeck C, Guven A,Kogan B and Mannikarottu A. Effects of L-arginineand L-NAME on chronic partial bladder outletobstruction in rabbit. American Journal ofPhysiology: Regulatory, Integrative andComparative Physiology 293(6):R2390–R9,October 2007.
Luciana B. Lopes
Lopes LB, Furnish E, Komalavilas P, Seal BL,Panitch A, Bentley MV and Brophy CM. Enhancedskin penetration of P20 phosphopeptide usingprotein transduction domains. European Journalof Pharmaceutics and Biopharmaceutics68(2):441-5, February 2008.
Komalavilas P, Penn RB, Flynn CR, Thresher J,Lopes LB, Furnish EJ, Guo M, Pallero MA, Murphy-Ullrich JE and Brophy CM. The small heat shock-related protein, HSP20, is a cAMP-dependentprotein kinase substrate that is involved in airwaysmooth muscle relaxation. American Journal ofPhysiology. Lung, Cellular and MolecularPhysiology 294(1):L69–78, January 2008.
William R. Millington
Yilmaz MS, Millington WR and Feleder C. The pre-optic anterior hypothalamic area mediates initia-tion of the hypotensive response induced bylipopolysaccharide in male rats. Shock29(2):232–237, 2008.
Millington WR. Sheep have the last word: Kappaand delta opioid receptors initiate hemorrhagichypotension. Acta Physiologica 191:1, 2007.
Millington WR and Göktalay G. Neurochemicalapproaches to addiction treatment in Pain andChemical Dependency (H. Smith H and S. Passik,eds.), New York: Oxford University Press, 2008.
Alexandre A. Steiner
Steiner AA, Turek VF, Almeida MC, Burmeister JJ,Oliveira DL, Roberts JL, Bannon AW, Norman MH,Louis JC, Treanor JJ, Gavva NR and RomanovskyAA. Nonthermal activation of transient receptorpotential vanilloid-1 channels in abdominal visceratonically inhibits autonomic cold-defense effec-tors. The Journal of Neuroscience 27:7459–7468,2007.
Pharmaceutical Sciences
PrezRepVF 4/15/09 1:41 PM Page 34
ACPHS 2008 // 35
Ootsuka Y, Blessing WW, Steiner AA andRomanovsky AA. Fever response to intravenousprostaglandin E2 is mediated by the brain butdoes not require afferent vagal signaling.American Journal of Physiology. Regulatory,Integrative and Comparative Physiology294:R1294–R1303, 2008.
Jeffrey M. Voigt
Mandalaywala NV, Chang S, Snyder RS,Levendusky MC, Voigt JM and Dearborn Jr. RE.The tumor suppressor, vitamin D3 up-regulatedprotein 1 (VDUP1), functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315:489-504, 2008.
M. Sertac Yilmaz
Yilmaz MS, Millington WR, and Feleder C. Thepreoptic anterior hypothalamic area mediates ini-tiation of the hypotensive response induced byLPS in male rats. Shock 29(2):232–237, 2008.
Cansev M, Yilmaz MS, Ilcol YO, Hamurtekin E andUlus IH. Cardiovascular effects of CDP-cholineand its metabolites: involvement of peripheralautonomic nervous system. European Journal ofPharmacology 577:129–142, 2007.
Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E andUlus IH. Intraperitoneal administration of CDP-choline and its cholinergic and pyrimidinergicmetabolites induce hyperglycemia in rats:Involvement of the sympathoadrenal system.Archives of Physiology and Biochemistry113(4/5):186-201, 2007.
Ilcol YO, Cansev M, Yilmaz MS, Hamurtekin E andUlus IH. Peripheral administration of CDP-cholineand its cholinergic metabolites increases seruminsulin: Peripheral muscarinic and nicotinic acetyl-choline receptors are both involved in its action.Neuroscience Letters 431(1):71–76, 2008.
Cansev M, Ilcol YO, Yilmaz MS, Hamurtekin E andUlus IH. Peripheral administration of CDP-choline,phosphocholine or choline increases plasmaadrenaline and noradrenaline concentrations.Autonomic and Autacoid Pharmacology28:41–58, 2008.
GRANTS
Richard E. Dearborn Jr.
PROJECT: Mutagenic analysis of conserved aminoacid function in the tumor suppressor Vitamin D3Up-regulated Protein 1 (VDUP1)
SPONSOR: Albany College of PharmacyIntramural Grant
TOTAL GRANT: $5,000
PROJECT PERIOD: 2007–2008
Carlos Feleder
PROJECT: The role of the spleen in the febrileresponse
SPONSOR: National Institutes of Health
TOTAL GRANT: $150,000
PROJECT PERIOD: October 2007–September2010
PROJECT: The spleen releases a splenic inhibitoryfactor that controls LPS fever
SPONSOR: American Association of Colleges ofPharmacy
TOTAL GRANT: $10,000
PROJECT PERIOD: January 2007–December2010
PROJECT: Splenic regulation of endotoxic fever
SPONSOR: Albany College of PharmacyIntramural Grant
TOTAL GRANT: $5,000
PROJECT PERIOD: 2007–2008
Arnold Johnson
PROJECT: Biomarkers predicting the severity ofobstruction-induced bladder dysfunction
SPONSOR: Merit Review Award, Dept. of VeteransAffairs
PRINCIPAL INVESTIGATOR: Robert M. Levin
TOTAL GRANT: $125,000
PROJECT PERIOD: April 2006–March 2010
PROJECT: A mechanism for TNF inducedendothelial dysfunction
SPONSOR: National Institute of Health, NHLBI
TOTAL GRANT: $200,000
PROJECT PERIOD: January 2005–January 2009
Robert M. Levin
PROJECT: Protection against ischemia andischemia followed by reperfusion by AntrodiaCamphorata
SPONSOR: Wellshine Pharmaceuticals
TOTAL GRANT: $40,000 per year
PROJECT PERIOD: 2007–2008
PROJECT: Biomarkers predicting the severity ofobstructive bladder dysfunction
SPONSOR: Veteran’s Administration MedicalCenter
TOTAL GRANT: $125,000 per year
PROJECT PERIOD: 2006–2010
Luciana Lopes
TITLE: Use of campul-based microemulsions astopical delivery systems
SPONSOR: Scholarship of Discovery Grant,Albany College of Pharmacy
TOTAL GRANT: $5,000
PROJECT PERIOD: May 2008–June 2009
Adwoa O. Nornoo
PROJECT: Detection of penicillin G in blisterpacks of various drugs packaged by Heartland,Inc.
SPONSOR: Office of the New York State AttorneyGeneral
TOTAL GRANT: $2,200
PROJECT PERIOD: October 2007–January 2008
Alexandre A. Steiner
PROJECT: Leptin is a pro-inflammatory cytokine:True or false?
SPONSOR: Scholarship of Discovery Grant,Albany College of Pharmacy
TOTAL GRANT: $4,500
PROJECT PERIOD: May 2008–June 2009
Jeffrey M. Voigt
PROJECT: Regulation of VDUP-1 expression inhuman tumor cells
SPONSOR: Albany College of PharmacyIntramural Grant
TOTAL GRANT: $5,000
PROJECT PERIOD: July 2008–June 2009
PROJECT: Post-translational modification ofVDUP-1 in human cells
SPONSOR: Albany College of PharmacyIntramural Grant
TOTAL GRANT: $5,000
PROJECT PERIOD: July 2007–June 2008
HaiAn Zheng
PROJECT: Computer 3D molecular modeling andanimation for pharmaceutics and pharmacyEducation
SPONSOR: Scholarship of Discovery andEducational Excellence, Albany College ofPharmacy
TOTAL GRANT: $5,000
PROJECT PERIOD: May 2008–May 2009
ABSTRACTS/PRESENTATIONS
Richard E. Dearborn
Voigt JM, Basle J and Dearborn Jr. RE.Phosphorylation of VDUP-1 in human U-87 MGglioma cells. American Association for CancerResearch Annual Meeting, San Diego, Calif., April2008.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC and Dearborn Jr. RE. Retinalaxon-dependent regulation of vitamin D3 up-reg-ulated protein 1 (VDUP1) tumor suppressorexpression in the Drosophila optic lobe.Neurobiology of Drosophila meeting, Cold SpringHarbor, N.Y., October 2007.
PrezRepVF 4/15/09 1:41 PM Page 35
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC and Dearborn Jr. RE. Retinalaxon-dependent regulation of vitamin D3 up-reg-ulated protein 1 (VDUP1) tumor suppressorexpression in the Drosophila optic lobe.Commission on Independent Colleges andUniversities Undergraduate Research Exposition,Albany, N.Y., January 2008.
Carlos Feleder
Marlow J, Yilmaz MS, Millington WR and FelederC. Dose-dependent mechanisms mediatelipopolysaccharide hypotension in male rats.Experimental Biology, San Diego, Calif., April2008.
Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of alpha-adrenergic receptors inthe preoptic anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology, San Diego, Calif., April2008.
Robert M. Levin
Levin RM. Update on studies on obstructive blad-der dysfunction. Lund University, Lund, Sweden,September 2007.
Levin RM. Ischemic etiology of obstructive blad-der dysfunction: Effect of Antrodia Camphorata.Antrodia Comphorata Symposium, Taipei, Taiwan,March 2008.
Levin RM. Ischemic etiologies of male and femaleurological dysfunctions. Veteran’s GeneralHospital, Taipei, Taiwan, March 2008.
Levin RM. Beneficial effects of AntrodiaComphorata. Taichung General Hospital, Taichung,Taiwan, March 2008.
Levin RM. Anti-ischemic effects of AntrodiaComphorata. Taipei General Hospital, Taipei,Taiwan, March 2008.
Luciana B. Lopes
Hosmer J, Reed R, Nornoo AO, Lopes LB.Influence of microemulsion composition on theskin penetration and percutaneous delivery ofProgesterone. 11th Annual American Associationof Pharmaceutical Scientists Northeast RegionalDiscussion Group, Rocky Hill, Conn., April 2008.
Komalavilas P, Lopes LB, Flynn CR, Smoke C, SealB, Panitch A and Brophy CM. Reduction of heatchock protein 27 phosphorylation inhibits thedevelopment of intimal hyperplasia. ExperimentalBiology 2008, San Diego, Calif., April 2008.
William R. Millington
Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of α-adrenergic receptors in thepreoptic area/anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.
Marlow J, Yilmaz MS, Millington WR and FelederC. Dose-dependent mechanisms mediatelipopolysaccharide (LPS) hypotension in malerats. Experimental Biology 2008, San Diego, Calif.,April 2008.
Adwoa O. Nornoo
Nornoo AO and Chikhale P. Microemulsion-basedformulations of Paclitaxel: Anticancer activityagainst rat glioma cells and intestinal permeability.2007 American Association of PharmaceuticalScientists Annual Meeting and Exposition, SanDiego, Calif., November 2007.
Nornoo AO and Zheng H. Pharmacokinetics andNMR characterization of Paclitaxel microemul-sions. 2007 American Association ofPharmaceutical Scientists Annual Meeting andExposition, San Diego, Calif., November 2007.
Alexandre A. Steiner
Romanovsky AA, Steiner AA, Turek VF, AlmeidaMC, Burmeister JJ, Oliveira DL, Roberts JL,Bannon AW, Norman MH, Louis J-C, Treanor JJSand Gavva NR. Non-thermal activation of TRPV1channels in abdominal viscera tonically inhibitsautonomic cold-defense effectors. 37th AnnualMeeting of the Society for Neuroscience, SanDiego, Calif., 2007.
Jeffrey M. Voigt
Basle J and Voigt JM. Phosphorylation of VDUP-1in human U87-MG glioma cells. AmericanAssociation for Cancer Research, San Diego.,Calif., April 2008.
M. Sertac Yilmaz
Yilmaz MS, Myer BS, Feleder C and MillingtonWR. Blockade of α-adrenergic receptors in thepreoptic area/anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.
Marlow J, Yilmaz MS, Millington WR and FelederC. A neural route signals the brain in endotoxichypotension: Role of the vagus nerve and α-adrenoceptors in the preoptic anterior hypothala-mic area. Experimental Biology 2008, San Diego,Calif., April 2008.
HaiAn Zheng
Nornoo AO and Zheng H. Pharmacokinetics andNMR characterization of paclitaxol microemulsion.American Association of PharmaceuticalScientists Annual Meeting, San Diego, Calif.,November 2007.
PrezRepVF 4/15/09 1:41 PM Page 36
ACPHS 2008 // 37
PUBLICATIONS
James Anderson
Anderson J and Applegate E. The psychologicalrobot: A new tool for learning. InternationalJournal of Teaching and Learning in HigherEducation 19(3):305-314, 2007.
Kenneth J. Blume
Blume KJ. The talented tenth and American for-eign policy: African-Americans in the U.S.Diplomatic Corps, 1865-1914. The Mind’s Eye: ALiberal Arts Journal (Massachusetts College ofLiberal Arts), 2007.
Blume KJ. Entries on Rush-Bagot Treaty, Anglo-American Treaty, Adams-Onis Treaty, Webster-Ashburton Treaty, Oregon Treaty, Treaty ofGuadalupe Hidalgo, Alaska Purchase, BurlingameTreaty, Hay-Herran Treaty and Hay-Bunau-VarillaTreaty in Encyclopedia of the Age of Imperialism:1800–1914 (Carl Cavanagh Hodge, ed.), Westport,Conn.:Greenwood Press, 2007.
Blume KJ. Entries on Alexander Clark, WilliamHenry Harrison Heard, William Frank Powell andJohn E. W. Thompson in African AmericanNational Biography (Henry Louis Gates andEvelyn Higginbottom, eds.), New York: OxfordUniversity Press, 2008.
Blume KJ. Review of Angus Curry’s The Officersof the CSS Shenandoah. H-Maritime, May 2007.
Blume KJ. Review of Eric J. Graham and ClydeBuilt’s Blockade Runners, Cruisers and ArmouredRams of the American Civil War. The NorthernMarine/Le Marin Du Nord, July 2007.
Margaret Lasch Carroll
Carroll ML. Prodigals’ dreams: John McGahern’sThat They May Face the Rising Sun. EstudiosIrlandeses 3:42-53, 2008.
Ray Chandrasekara
Chandrasekara R. Borders, boundaries, bodies:Caliban re-membered. International Journal ofthe Humanities 5(10):189-98, 2007.
Chandrasekara R and Polimeni JM. Water andnational security. International Journal ofInterdisciplinary Social Sciences 2(6):11-20, 2008.
Chandrasekara R. Entries on When the RainbowGoddess Wept and Ninotchka Rosca inEncyclopedia of American EthnicLiterature/Asian American volume (Seiwong Oh,ed.), Facts on File, 2008.
J. Daniel d’Oney
d’Oney JD. Watered by tempests: Hurricanes inthe cultural fabric of the United Houma Nation.American Indian Culture and Research Journal32(2):11-26, 2008.
d’Oney JD. River queens, sternwheelers andcanyon cats. Pacific Northwest Quarterly.99(1):40-42, Winter 2007/2008.
Martha A. Hass
Siflinger-Birnboim A, Levin RM and Hass MA.Partial outlet obstruction of the rabbit urinarybladder induces selective protein oxidation.Neurourology and Urodynamics 26:1-7, 2007.
Hass MA, Siflinger-Birnboim A and Levin RM.Hydroxynonenal in obstructed urinary bladderdisease. Federation of American Societies forExperimental Biology Journal 21(6):lb31, April2007.
Kevin M. Hickey
Hickey KM and Karatsolis A. A Rocky-Horror-Picture Show pedagogy: Tablet PC use inHumanities and Communication student-centeredclassrooms. University College of the FraserValley Research Review 1(3): 26-37.
Hickey KM. Entries on Exploration and Explorers,Africa; Ralph Ellison; Morant Bay Rebellion; Race,History of; and Soukous in Africa and theAmericas: Culture, Politics, and History (3 vol-umes, Richard M. Juang and Noelle Morrissette,eds.). Santa Barbara: ABC-CLIO Press, 2008.
Marion Jacobson
Jacobson M. Searching for rockordion: Thechanging image of the accordion in America inthe Twentieth Century. American Music 3: 123-159.
Andreas Karatsolis
Hickey KM and Karatsolis A. A Rocky-Horror-Picture Show pedagogy: Tablet PC use inHumanities and Communication student-centeredclassrooms. University College of the FraserValley Research Review 1(3): 26–37.
Karatsolis A. Revamping the honor code in a pro-fessional curriculum. Integrity Matters: Center forAcademic Integrity, 2008.
Karatsolis A. Tablets as writing canvases and con-struction sites in The Impact of Tablet PCs andPen-based Technology on Education: Vignettes,Evaluations, and Future Directions (Berque, et al,eds.), Purdue University Press, September 2007.
Michael Pittman
Pittman M. Soul making in all and everything.Proceedings of the 12th International HumanitiesConference: All and Everything InternationalHumanities Conference 2007.
Laura Rogers
Rogers L. Finding our way from within: Criticalpedagogy in a prison writing class. Open Words2(1): 22–48, Spring 2008.
Sandra Winn
Winn S. George Elder’s story “Passion andSparks.” The Authentic Dissertation: AlternativeWays of Knowing, Research and Representation(Four Arrows AKA Don Trent Jacobs). New York:Routledge Press. pp 175-184.
ABSTRACTS/PRESENTATIONS
Patricia Baia
Baia P. CDETG: Active learning: In or outside theclassroom. Albany College of Pharmacy, Albany,N.Y., June 2008.
Kenneth J. Blume
Blume KJ. Who needs to know about theSchlieffen Plan? Focusing on the ’big picture’ andWorld War I. World History Association AnnualConference, University of Wisconsin, Milwaukee,Wisc. July 2007.
Margaret Carroll
Carroll M. Conflict, coexistence and community:Creatures of the Earth by John McGahern.American Conference of Irish Studies NationalConference, St. Ambrose University, Davenport,Iowa, April 2008.
Ray Chandrasekara
Chandrasekara R. Borders, boundaries, bodies:Caliban re-membered. International HumanitiesConference, Paris, France, July 2007.
Chandrasekara R. Water and state security.International Social Science Conference, Grenada,Spain, July 2007.
J. Daniel d’Oney
D’Oney JD. Have You Heard: The Past in FirstPerson from the T. Harry Williams Center for OralHistory (researched and curated the section onthe United Houma Nation for museum exhibit).Hill Memorial Library, Baton Rouge, October 22,2007–March 30, 2008.
Ellen B. Duffy
Duffy EB and Harton JA. Anthrax lethal toxinsinduces caspase-independent apoptosis in humanand murine macrophage cell lines. AmericanSociety for Microbiology 108th General Meeting,Boston, Mass., June 2008.
Martha A. Hass
Hass MA, Siflinger-Birnboim A and Levin RM.Hydroxynonenal in obstructed urinary bladderdisease. Federation of American Societies forExperimental Biology/ Annual ExperimentalBiology meeting, Washington, D.C., April 2007.
Kevin M. Hickey
Hickey KM. Diverting “les flots souterrains” to cul-tivate the cosmopolitans in Veronique Tadjo’sL’Ombre d’Imana (The Shadow of Imana). 34thAnnual Conference of the African LiteratureAssociation, Macomb, Ill., April 2008.
Marion Jacobson
Jacobson M. Italian dance hall culture: The accor-dion as a symbol of pluralism and ethnicity.Italians in the Americas Conference, New York,N.Y., April 2008.
Andreas Karatsolis
Karatsolis A. Designing effective websites:Innovation in project-based learning. AmericanAssociation of Colleges of Pharmacy AnnualMeeting, Orlando, Fla., July 2007.
Arts and Sciences
PrezRepVF 4/15/09 1:41 PM Page 37
Erika A. Muse
Muse EA. From theory to practice: Building com-petencies in intercultural encounters in AsianAmerica. Association for Asian American Studies,Chicago, Ill., April 2008.
Michael Pittman
Pittman M. Gurdjieff: Religion and its discontents.American Society for Esoteric Studies Conferencein Charleston, S.C., May-June, 2008.
Pittman M. Gurdjieff’s view of education in All andEverything. Armenia-Gurdjieff Conference,Yerevan, Armenia, July 2007.
Laura Rogers
Rogers L. Diving Into prison teaching: MinaShaughessy, teacher development and the reali-ties of prison teaching. Conference on CollegeComposition and Communication, New Orleans,La., April 2008.
Elisabeth A. Vines
Vines E. Pictures of potatory pleasures:Nineteenth century France. Fourth InternationalConference on Drugs and Alcohol in History,Guelph, Ontario, Canada, August 2008.
Sandra Winn
Winn S. Our strategy for achieving toleranceamong our campus community. NationalAssociation for Multicultural Education meeting,Baltimore, Md., October-November 2007.
Winn S. Implications for moral education practicesfrom the field. Association for Moral Education,New York, N.Y., November 2007.
EXHIBITIONS
Elisabeth E. Vines
Vines EA. Oil works (21 recent paintings).Bethlehem Public Library, Delmar, N.Y., January2008.
Vines EA. New Mustache. Third Annual Members’Show, Albany Center Gallery, Albany, N.Y.,December 2007–January 2008.
Vines EA. Window Series (11 oil paintings). Café atthe Honest Weight Food Co-op, Albany, N.Y.,September 2007.
GRANTS
Kenneth J. Blume
PROJECT: Sable Diplomats: African Americans inthe U.S. Diplomatic Corps, 1865-1914
SPONSOR: Albany College of Pharmacy
TOTAL GRANT: $3,240
PROJECT PERIOD: 2007–2008
Martha Hass
PROJECT: Ischemic etiology of obstructive blad-der dysfunction
SPONSOR: National Institutes of Health—NationalInstitute of Diabetes, Digestive and KidneyDisease
PRINCIPAL INVESTIGATOR: Robert Levin
TOTAL GRANT: $1,154,280
PROJECT PERIOD: 2004–2008.
PROJECT: The role of the spleen in the febrileresponse
SPONSOR: National Institutes of Health—Neuroendocrinology, Neuroimmunology andBehavior
PRINCIPAL INVESTIGATOR: Carlos Feleder
TOTAL GRANT: $194,553
PROJECT PERIOD: 2008–2010.
Michael Pittman
PROJECT: Armenia-Gurdjieff Conference (organ-izer)
SPONSOR: Indications Press
TOTAL GRANT: $600
PROJECT PERIOD: July 2007
Health Sciences
ABSTRACTS/PRESENTATIONS
Indra Balachandran
Balachandran I and Walker J. Curriculum map-ping. 55th Annual Meeting of the AmericanSociety of Cytopathology, Houston, Tex.,November 2007.
Balachandran I. Small blue cell tumors of child-hood: Case study approach. TeleconferenceNetwork of Texas series, University of TexasHealth Science Center, San Antonio, Tex., March2008.
Bolded names indicate ACPHS faculty collaborators
PrezRepVF 4/15/09 1:41 PM Page 38
ACPHS 2008 // 39
BSPS STUDENTS
PUBLICATIONS
Juan Y-S, Mannikarottu A, Hydery T, Lin W-Y,Kogan BA, Whitbeck C, Leggett RE, Levin RM.Coenzyme Q10 protect against ischemia / reper-fusion induced biochemical and functionalchanges in rabbit urinary bladder. Molecular andCellular Biochemistry 311:73-80, 2008.
Juan Y-S, Levin RM, Hydery T, Chuang SM, Li S,Leggett RE, Huang CH, Mannikarottu A.Protective effect of coenzyme Q10 plus lipoic acidagainst obstructive bladder dysfunctions in therabbit. Journal of Urology (In Press).
Lin W-Y, Rehfuss A, Whitbeck C, Juan W-S,Chichester, Mannikarottu A, Levin RM. Effect ofLetrozole on female rabbit Urinary bladder func-tion. BJU International 100:1391-1395, 2007.
Lin W-Y, Rehfuss A, Whitbeck C, Levin RM. Effectof coenzyme Q10 and α-lipoic acid on theresponse of the rabbit urinary bladder to repeti-tive stimulation and in vitro ischemia. Urology72(1):214-9, July 2008 [Epub, February 2008].
Lin W-Y, Radu F, Schuler C, Leggett RE,Mannikarottu A, Levin RM. Effect of ovariectomyand estrogen therapy on the free fatty acid con-tent, endogenous lipase activity, and phospholipidcontent of the rabbit urinary bladder. BJUInternational 102(7):885-9, September 2008[EPub, May 2008]
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM, Dearborn Jr RE. Thetumor suppressor, vitamin D3 up-regulated pro-tein 1 (VDUP1), functions downstream of REPOduring Drosophila gliogenesis. DevelopmentalBiology 315:489-504, 2008.
Yilmaz, MS, Göktalay G, Myer BS, Millington WR,Cutrera R, Feleder C. Lipopolysaccharide-inducedhypotension is mediated by a neural pathwayinvolving the vagus nerve, the nucleus tractussolitarius and alpha-adrenergic receptor in thepreoptic anterior hypothalamic area. Journal ofNeuroimmunology 203(1):39-49, October 2008.
ABSTRACTS
Juan Y-S, Mannikarottu A, Hydery T, Kogan BA,Schuler C, Leggett RE, Levin RM, Coenzyme Q10and alpha lipoic acid as a treatment for partialbladder outlet obstruction induced bladder dys-function. American Urological Society Meeting,Orlando, Fla., May 2008.
Radu F, Lin W-Y, Chichester P, Leggett RE,Mannikarottu A, Levin RM. Effect of ovariectomyand estrogen administration on free fatty acid,and phospholipid concentrations of the rabbit uri-nary bladder muscle and mucosa. AmericanUrological Society Meeting, Orlando, Fla., May2008.
Nornoo AO, Owusu-Obeng A, Myer BS, NguyenH, Reed R. Effect of oral microemulsions (MEs) onthe permeability (peff) of paclitaxel (PAC) acrossrat GIT and caco-2 cell monolayers. AmericanAssociation for Cancer Research Annual Meeting,Los Angeles, Calif., April 2007.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. Cold Spring HarborNeurobiology of Drosophila Meeting, Cold SpringHarbor, NY, October 2007.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. CICU UndergraduateResearch Exposition, Albany, NY, January 2008.
Voigt JM, Basle J, Dearborn Jr, RE.Phosphorylation of VDUP-1 in human U-87 MGglioma cells. AACR Annual Meeting, San Diego,Calif., April 2008.
Marlow J, Yilmaz MS, Millington W, Feleder C.Dose-dependent mechanisms mediatelipopolysaccharide hypotension in male rats.Experimental Biology 2008, San Diego, Calif.,April 2008.
Yilmaz MS, Myer BS, Feleder C, Millington W.Blockade of alpha-adrenergic receptors in thepreoptic anterior hypothalamus preventslipopolysaccharide evoked hypotension.Experimental Biology 2008, San Diego, Calif.,April 2008.
PHARM.D. STUDENTS
PUBLICATIONS
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Voigt JM, Dearborn Jr RE. Thetumor suppressor, vitamin D3 up-regulated protein1 (VDUP1), functions downstream of REPO duringDrosophila gliogenesis. Developmental Biology315:489-504, 2008.
Nornoo A, Zheng H, Lopes LB, Reed R, et al. Oral microemulsions of paclitaxel in situ andphamacokinetic studies. European Journal of Pharmaceutics and Biopharmaceutics71(2):310–7, February 2009.
ABSTRACTS
Wong P, Blustein L, Policastro C, Zheng H.Pharmaceutics Online-Homework: CalculationPractice and Evaluation in Large-Class. AACPAnnual Conference, 2008.
Hosmer J, Reed R, Nornoo N, Lopes LB. Influenceof microemulsion composition on the skin pene-tration and percutaneous delivery of proges-terone. 11th Annual AAPS Northeast RegionalDiscussion Group, Rocky Hill, Conn., April 2008.
Nornoo AO, Owusu-Obeng A, Myer BS, NguyenH, Reed R. Effect of oral microemulsions (MEs) onthe permeability (peff) of paclitaxel (PAC) acrossrat GIT and caco-2 cell monolayers. AmericanAssociation for Cancer Research Annual Meeting,Los Angeles, Calif., April 2007.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. Cold Spring HarborNeurobiology of Drosophila Meeting, Cold SpringHarbor, NY, October 2007.
Mandalaywala NV, Chang S, Snyder RG,Levendusky MC, Dearborn Jr, RE. Retinal axon-dependent regulation of vitamin D3 up-regulatedprotein 1 (VDUP1) tumor suppressor expression inthe Drosophila optic lobe. CICU UndergraduateResearch Exposition, Albany, NY, January 2008.
Department of Pharmaceutical Sciences—Student Publications
Bolded names indicate ACPHS students
PrezRepVF 4/15/09 1:41 PM Page 39
Go green and make your gift online www.acphs.edu, click on Online Giving.ACPHS accepts both MasterCard and Visa
Telephone 518.694.7253
Toll Free 888.203.8010
Please make checks payable to Albany College of Pharmacy and Health Sciences and mail to
Office of Institutional Advancement
Albany College of Pharmacy and Health Sciences
106 New Scotland Ave.
Albany, New York 12208
ENABLE STUDENT
AND FACULTY RESEARCH
ENSURE STATE-OF-THE-ART
RESEARCH LABS AND
PROGRESSIVE TECHNOLOGIES
SUPPORT STUDENT
SCHOLARSHIP AND
FACULTY DEVELOPMENT
AcademicExcellence +ResearchOpportunities
Make a difference to the ACPHS community.
The possibilities are endless with your gift.
PrezRepVF 4/15/09 1:41 PM Page 40
OFFICERS
Kandyce J. Daley ’74 CHAIR
Hugh A. Johnson VICE CHAIR
Christopher Del Vecchio ’88 TREASURER
Bridget-ann Hart ’80 SECRETARY
TERM TRUSTEES
Stephen C. AinlayJames E. Bollinger ’58Robert S. BuschHerbert ChorbajianJ. Gordon Dailey ’57Richard H. Daffner ’63Francis J. DiLascia ’54Melvin Friedland ’58Geno J. Germano Jr. ’83Zachary I. Hanan ’63David M. Kile ’74Jeannette S. Lamb ’57Joseph LapetinaThomas O. MaggsRobert F. McGaugh ’57Christopher MitiguyFouad MorkosRichard G. Robison ’52
CHAIRMAN EMERITUS
Alfred J. Collins Jr. ’53
TRUSTEES EMERITUS
Michael BetteKenneth M. Nirenberg
OFFICE OF GRANTS ADMINISTRATION
Sunita ChowfinGRANTS ADMINISTRATOR
518.694.7144sunita.chowfin@acphs.edu
PHARMACEUTICAL RESEARCH INSTITUTE
Shaker A. Mousa, Ph.D.EXECUTIVE VICE PRESIDENT AND CHAIRMAN
518.694.7397shaker.mousa@acphs.edu
Vicki A. DiLorenzoVICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT
518.694.7331vicki.dilorenzo@acphs.edu
David ZdunczykASSISTANT VICE PRESIDENT OF INSTITUTIONAL ADVANCEMENT
518.694.7251david.zdunczyk@acphs.edu
Donna BeebeDIRECTOR OF MAJOR GIFTS
518.694.7125donna.beebe@acphs.edu
Michael J. BuckleyMAJOR GIFTS OFFICER
518.694.7126michael.buckley@acphs.edu
Gil ChorbajianEXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS
518.694.7394gil.chorbajian@acphs.edu
Deanna Ennello-ButlerDIRECTOR OF ADVANCEMENT RESEARCH
518.694.7305deanna.ennello-butler@acphs.edu
Candace MaddenSYSTEMS ADMINISTRATOR
518.694.7156candace.madden@acphs.edu
Patrick RathbunASSISTANT DIRECTOR OF MARKETING AND COMMUNICATIONS
518.694.7131patrick.rathbun@acphs.edu
Deborah S. ReutterCOORDINATOR OF INSTITUTIONAL ADVANCEMENT
518.694.7220debbie.reutter@acphs.edu
Christine A. ShieldsDIRECTOR OF COLLEGE PUBLICATIONS
518.694.7393alumni@acphs.edu
Christina Spinelli SanvidgeCOORDINATOR OF DONOR RELATIONS AND STEWARDSHIP
COORDINATOR OF ACPHS ACADEMY
518.694.7127christina.spinelli@acphs.edu
James J. Gozzo, Ph.D.PRESIDENT
Mehdi Boroujerdi, Ph.D., Pharm.D.DEAN
A L B A N Y C O L L E G E O F P H A R M AC Y A N D H E A LT H S C I E N C E S
Office of Institutional Advancement
Research
Board of Trustees
CoverF 4/15/09 1:43 PM Page 4
NON-PROFIT ORG
US POSTAGE
PaidALBANY NY
PERMIT NO. 349
CoverF 4/15/09 1:43 PM Page 1
top related